

REVIEW

Transgenic and physiological mouse models give insights into different aspects of amyotrophic lateral sclerosis

Francesca De Giorgio^{1,*}, Cheryl Maduro^{1,*}, Elizabeth M. C. Fisher^{1,‡} and Abraham Acevedo-Arozena^{2,‡}

ABSTRACT

A wide range of genetic mouse models is available to help researchers dissect human disease mechanisms. Each type of model has its own distinctive characteristics arising from the nature of the introduced mutation, as well as from the specific changes to the gene of interest. Here, we review the current range of mouse models with mutations in genes causative for the human neurodegenerative disease amyotrophic lateral sclerosis. We focus on the two main types of available mutants: transgenic mice and those that express mutant genes at physiological levels from gene targeting or from chemical mutagenesis. We compare the phenotypes for genes in which the two classes of model exist, to illustrate what they can teach us about different aspects of the disease, noting that informative models may not necessarily mimic the full trajectory of the human condition. Transgenic models can greatly overexpress mutant or wild-type proteins, giving us insight into protein deposition mechanisms, whereas models expressing mutant genes at physiological levels may develop slowly progressing phenotypes but illustrate early-stage disease processes. Although no mouse models fully recapitulate the human condition, almost all help researchers to understand normal and abnormal biological processes, providing that the individual characteristics of each model type, and how these may affect the interpretation of the data generated from each model, are considered and appreciated.

KEY WORDS: Amyotrophic lateral sclerosis, ALS, Transgenic, Knock-in, ENU, Gene targeted

Introduction

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder first described in 1869 by Jean-Martin Charcot (Charcot and Joffroy, 1869). It has a mean incidence of ~2/100,000 worldwide and a prevalence of ~6/100,000 in Europe (Costa and de Carvalho, 2016; Marin et al., 2016), with a lifetime risk of ~1 in 300 in Western populations (Brown and Al-Chalabi, 2017). ALS patients typically present a focal onset, starting as unilateral limb weakness or bulbar impairment. Clinical symptoms usually start in mid-life and are a consequence of the dysfunction and death of motor neurons (MNs) in the primary motor cortex,

brainstem and spinal cord, which causes spasticity, weakness and muscle wasting, gradually leading to paralysis and death from respiratory failure, typically less than 5 years from diagnosis (Huynh et al., 2016; Van Damme et al., 2017).

There are no effective treatments for ALS apart from daily care and support to counteract the symptoms. Currently, there are only two US Food and Drug Administration (FDA)- and European Medicines Agency (EMA)-approved neuroprotective drugs that increase the lifespan of some patients by a few months: Riluzole, which blocks excessive glutamatergic neurotransmission, and Edaravone, which prevents oxidative stress damage.

Although 90% of ALS patients have sporadic (sALS) disease without apparent family history, ~5-10% of cases are familial (fALS), usually showing monogenic autosomal dominant inheritance (Brown and Al-Chalabi, 2017). In 1993, the first causative gene for ALS was discovered, encoding the enzyme Cu/Zn superoxide dismutase 1 (*SOD1*) (Rosen et al., 1993). Research shows that *SOD1*-ALS accounts for ~20% of fALS and ~2% of sALS, with >150 mutations identified throughout the coding region and causing an unknown toxic gain of function (GOF) (Saccon et al., 2013; Kaur et al., 2016). *SOD1* is ubiquitously expressed and important for the removal of free radicals, although it likely has other non-canonical roles; for example, as a transcriptional regulator under oxidative stress, possibly as an RNA-binding protein and a signalling molecule (Bunton-Stasyshyn et al., 2015).

Since the discovery of *SOD1*'s association with ALS, mutations in more than 20 genes were found to be causative, most with an autosomal-dominant pattern of transmission, together with >30 potential disease-modifying genes (Li and Wu, 2016). Causative genes include the chromosome 9 open reading frame 72 (*C9ORF72*), in which an intronic hexanucleotide repeat expansion gives rise to ALS. This mutation is the most common cause of fALS, and is found in up to 40% of fALS and ~9% of sALS in Caucasians (DeJesus-Hernandez et al., 2011; Renton et al., 2011; Goldstein et al., 2018). Other well known 'ALS genes' include TAR DNA-binding protein (*TARDBP*; encoding TDP-43), found in ~5% of fALS and ~2% of sALS, and fused in sarcoma (also known as FUS RNA-binding protein; *FUS*), found in ~6% of fALS and ~1% of sALS (Ingre et al., 2015; Tarlarini et al., 2015). TDP-43 and FUS are RNA-binding heterogeneous nuclear ribonucleoproteins (hnRNPs) mainly localised in the nucleus, and are involved in mRNA splicing, gene transcription and microRNA maturation, mRNA shuttling from the nucleus to the cytoplasm and stress granule formation. Cytoplasmic mislocalisation and nuclear depletion of TDP-43 is a key feature of most ALS cases and may contribute to disease pathogenesis (Guerrero et al., 2016). Protein aggregates containing truncated hyperphosphorylated and/or ubiquitinated TDP-43 are found within MNs in >95% of ALS-affected brains and spinal cords (Chou et al., 2018), and can occur in other neurological disorders, including Alzheimer's, Parkinson's and Huntington's diseases, highlighting

¹Department of Neuromuscular Diseases, UCL Institute of Neurology, and MRC Centre for Neuromuscular Disease, University College London, Queen Square, London WC1N 3BG, UK. ²Unidad de Investigación Hospital Universitario de Canarias, Fundación Canaria de Investigación Sanitaria and Instituto de Tecnologías Biomédicas (ITB), La Laguna, 38320 Tenerife, Spain.

*These authors contributed equally to this work

‡Authors for correspondence (elizabeth.fisher@ucl.ac.uk; aacevedo@ull.edu.es)

 E.M.C.F., 0000-0003-2850-9936; A.A.-A., 0000-0001-6127-7116

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

the importance of TDP-43 in neurodegeneration (Liu et al., 2017; St-Amour et al., 2018).

Other genes less frequently mutated in ALS include coiled-coil-helix-coiled-coil-helix domain-containing 10 (*CHCHD10*) (Bannwarth et al., 2014), kinesin family member 5A (*KIF5A*) (Brenner et al., 2018), matrin 3 (*MATR3*) (Johnson et al., 2014), optineurin (*OPTN*) (Maruyama et al., 2010), profilin 1 (*PFN1*) (Wu et al., 2012), senataxin (*SETX*) (Chen et al., 2004), sequestosome 1 (*SQSTM1/p62*) (Fecto, 2011), TANK-binding kinase 1 (*TBK1*) (Cirulli et al., 2015; Freischmidt et al., 2015), ubiquilin 2 (*UBQLN2*) (Deng et al., 2011), valosin-containing protein (*VCP*) (Johnson et al., 2010) and VAMP-associated protein B and C (*VAPB*) (Nishimura et al., 2004). As each new gene is identified, the next step is to make a mouse model. There are different types of mutant mice, which yield different insights and should be used to address different research questions.

Mouse models of ALS

We know little of early-stage ALS pathomechanisms, and we still have a lot to learn about the disease trajectories for fALS and sALS. Here, we discuss the main features of the different types of mouse models that are helping us to elucidate the molecular pathology of ALS and its phenotypic implications: transgenic mice, and targeted

and ENU mutant mice (Fig. 1). We then focus on comparing the phenotypes of mice with ALS gene mutations for which at least two of these types of model have been published; namely, *FUS*, *SOD1*, *TARDBP*, *VAPB*, *VCP* and *UBQLN2*.

Transgenic mouse models

ALS is mostly an autosomal-dominant disorder and therefore the majority of mouse models have been transgenic lines, made by randomly inserting human (in most cases) mutant ALS genes into the mouse genome (Table 1). This is a fast method of producing new strains and, because the disease is dominant, the phenotype usually manifests, despite the presence of intact orthologous mouse genes. Indeed, the first model of ALS, the *SOD1^{G93A}* transgenic strain [Tg(*SOD1**G93A)1Gur], was published a year after the discovery of *SOD1*-ALS mutations in humans (Gurney et al., 1994) (Table 1A) and remains the most commonly used ALS mouse model. Owing to the early onset, fast disease progression towards an early humane endpoint, progressive MN loss and low variability of the phenotype on defined genetic backgrounds, the *SOD1^{G93A}* transgenic strain has become the workhorse for testing therapeutics aimed at ameliorating ALS.

Around 30 *FUS* and *TARDBP* mutant transgenic lines have also been created, with variable levels of MN degeneration (Table 1B,C).




Fig. 1. Features of transgenic versus physiological mouse models for studying ALS. Examples from Table 1, showing potential windows of ALS pathology to investigate using transgenic or physiological mouse models; lengths of arrows correspond, approximately, to the severity of the phenotype on either heterozygous or homozygous mice at the oldest age measured, as per the references. We note that with respect to ALS genetic models, the *SOD1* G93A (Gurney et al., 1994) mouse was the first transgenic line. We believe that *Vcp* R155H (Badadani et al., 2010; Yin et al., 2012) was the first gene-targeted model, the *Sod1* D83G (Joyce et al., 2015) line was the first ENU mouse model, and the FUSDelta14 model (Devoy et al., 2017) was the first genomically humanised knock-in to the endogenous mouse locus, although this is a partial humanisation; see Table 1.

Table 1. Mouse models of ALS for which both transgenic and knock-in strains are published

Strain name	Transgenic/gene-targeted knock-in/ENU	Genetic background	Protein	Inclusions/aggregates	Gliosis	MA/MD	NMJ loss	Final-stage disease (terminal MN loss)	Survival (weeks)	Behavioural analysis	Other phenotypes	Reference
(A) SOD1 mouse models												
WT hSOD1 (JAX 002297)	Transgenic Promoter: hSOD1	C57BL/6×S/JL	High hSOD1 expression with increased enzyme activity	Ubiquitin; P	P	Mild	ND	Earlier signs: 30-50 weeks; MN loss: 20-30% at ~104 weeks	75-104	Mild motor coordination impairment	Argyrophilic fibre degeneration in SC.	(Gurney et al., 1994; Jaarsma et al., 2000)
WT hSOD1	Transgenic Promoter: hSOD1	C57BL/6×CBA	hSOD1 expressed 50× higher than endogenous mSOD1 but with low enzyme activity	Inclusions: P SOD1; P	P	ND	ND	Earlier signs: ~36 weeks; MN loss: ~41% at late stage	~52	Mild motor coordination impairment	Heavy vacuolisation in subiculum, weight loss, loss of Purkinje cells.	(Graffino et al., 2013)
SOD1 A4V	Transgenic Promoter: hSOD1	C57BL/6×S/JL	hSOD1; low expression levels with no enzyme activity	Ab	Ab	Ab	Ab	Ab	Normal	ND	A4V/hSOD1 double transgenics show phenotype at ~35 weeks and die at ~45 weeks of age.	(Gurney et al., 1994; Deng et al., 2006)
SOD1 G37R (JAX 008342)	Transgenic Promoter: hSOD1	C57BL/6J×C3H/HeJ	hSOD1; low expression levels with no enzyme activity	Ubiquitin; P	P	P	ND	Earlier signs: ~11-17 weeks; end-stage paralysis: P	25-29	Motor coordination impairment and cognitive impairment	Develop rigid thoracolumbar kyphosis.	(Wong et al., 1995; Filali et al., 2011)
SOD1 G37R	Transgenic Promoter: hNFL	C57BL/6J×C3H/HeJ	hSOD1 4× higher expression than endogenous SOD1	ND	ND	ND	ND	Abnormal	Normal	Normal	Ab	(Pramatarova et al., 2001)
SOD1 H46R	Transgenic Promoter: hSOD1	BDF1 (C57BL/6×DBA/2)	hSOD1	Inclusions: P SOD1; P Ubiquitin; P	P	ND	ND	Earlier signs: 20 weeks; MN loss: % ND	24	Motor coordination impairment	Body weight loss.	(Chang-Hong et al., 2005)
SOD1 H46R/H48Q	Transgenic Promoter: hSOD1	C3H/HeJ×C57BL/6J	hSOD1; high expression but inactive protein	Inclusions: P Ubiquitin; P	P	ND	ND	Earlier signs: 17-25 weeks; MN loss: % ND; end-stage paralysis: ~21 weeks	ND	Motor coordination impairment	Hyaline, thioflavin-S-positive inclusions.	(Wang et al., 2002)
SOD1 H46R/H48Q/H63GH120G	Transgenic Promoter: hSOD1	C3H/HeJ×C57BL/6J	hSOD1; high expression but inactive protein	Inclusions: P SOD1; P Ubiquitin; P	P	ND	ND	Earlier signs: 35-52 weeks; MN loss: % ND; end-stage paralysis: 21-25 weeks; no final MN loss	44-52	Motor coordination impairment	Thioflavin-S-positive inclusions.	(Wang et al., 2003)
SOD1 L84V	Transgenic Promoter: hSOD1	ND	hSOD1	Ab	Ab	Ab	Ab	Earlier signs: 26-30 weeks	26-30	ND	ND	(Tobisawa et al., 2003)
SOD1 G85R (JAX 008248)	Transgenic (G85R/WT hSOD1) Promoter: hSOD1	ND	hSOD1; low expression	Inclusions: P SOD1; P Ubiquitin; P	P	P	ND	Earlier signs: 26-35 weeks; MN loss: % ND; end-stage paralysis: 2 weeks after initial signs	28-37	Progressive motor coordination impairment	Late onset (>34 weeks), but rapid progression to paralysis.	(Bruijn et al., 1997)
SOD1 Thy1.2-G85R (EGFP) bicistronic	Transgenic Promoter: Thy 1.2	C57BL/6	hSOD1; high expression but low metabolic stability	Ab	Ab	ND	Ab	Ab	Normal	Ab	Ab	(Lino et al., 2002)
SOD1 G85R	Transgenic (also generated G85R/WT hSOD1) Promoter: hSOD1	C57BL/6J	hSOD1; high expression. Loss of endogenous SOD1 activity and mutant SOD1	Inclusions: P SOD1; P	ND	ND	P	Earlier signs: 44-48 weeks; MN loss: significant (% ND); disease duration ~6-6 weeks	50-54	Progressive motor coordination impairment	ND	(Wang et al., 2009)
SOD1 G86R (JAX 005110)	Transgenic Promoter: mSod1	FVBN	mSOD1; increased endogenous expression	ND	ND	ND	ND	Earlier signs: 13-17 weeks; MN loss: % ND	17	Motor coordination impairment	Pyknosis and karyorrhexis in MNs. Profound muscle wasting and unable to take food and water.	(Ripps et al., 1995)
SOD1 GFAP-G86R	Transgenic Promoter: hGFAP	C57BL/6/CBA	Increased mSOD1 expression, correlates with copy number	Ab	ND	Ab	Ab	Earlier signs: >70 weeks; no final MN loss	>70	Normal	Ascytic morphology changes.	(Wong et al., 1995)
SOD1 D90A	Transgenic Promoter: hSOD1	C57BL/6 S.JL×C5BL/6J Bom	hSOD1; high expression and activity (6-8× higher than that of Nlg in CNS)	Inclusions: P SOD1; P	P	ND	ND	Earlier signs: 52 weeks; 40% loss of ventral horn neurons; disease duration ~50 days	61	Motor coordination impairment	HOMs: distended bladder (resembling HOM D90A patients) and vacuoles throughout ventral neurophili.	(Jonsson et al., 2006)
SOD1 G93A (JAX 002726)	Transgenic Promoter: hSOD1	C57BL/6 S.JL×C57BL/6	hSOD1; high expression	Inclusions: P	P	P	P	Earlier signs: 13-17 weeks; MN loss: 50% at ~17 weeks; end-stage paralysis: ~19 weeks	17-26	Motor coordination impairment	Females survive longer than males. Anxiety-like behaviour, alterations in spatial navigation learning and memory.	(Gurney et al., 1994; Tu et al., 1996; Deng et al., 2006; Quarta et al., 2015)

Continued

Table 1. Continued

Strain name	Transgenic/gene-targeted knock-in/ENU	Genetic background	Protein	Inclusions/aggregates	Gliosis	MA/MD	NMJ loss	Final-stage disease (terminal MN loss)	Survival (weeks)	Behavioural analysis	Other phenotypes	Reference
SOD1 G93A (JAX 002300)	Transgenic Promoter: hSOD1	C57BL/6 SJLxC57BL/6	hSOD1; lower expression	Inclusions: P	P	P	P	Earlier signs: ~24-34 weeks; MN loss: >50%; end-stage paralysis: at 29-39 weeks	29-39	Motor coordination impairment. Low copy Gurney G93A line	Females survive longer than males.	(Gurney et al., 1994; Alexander et al., 2004; Jaarsma et al., 2000)
SOD1 Thy1.2-G93A (EGFP) bicistronic	Transgenic Promoter: Thy 1.2	C57BL/6	hSOD1; high expression	Ab	Ab	ND	Ab	Ab	Normal	Ab	Ab	(Lino et al., 2002)
SOD1 Thy1.2-G93A (JAX 008230)	Transgenic Promoter: Thy 1.2	FVBxBCBA	hSOD1; low expression	Inclusions: P SOD1: P Ubiquitin: P	P	ND	P	Earlier signs: 54-104 weeks; MN loss: ~40%	62->104	Motor coordination impairment	Non-focal onset. Terminal mice show severe weight loss >30%. Age-dependent clinical/pathological motor abnormalities in HEM. Only 1/3 of G127X mice showed foreleg onset, but rapid disease course (7-10 days after first sign). No thioflavin-S-positive inclusions in BS or SC unlike other ALS mice.	(Jaarsma et al., 2008)
SOD1 G127X	Transgenic Promoter: hSOD1	C57BL/6/CBA xC57BL/6J	hSOD1; low expression and no activity	Inclusions: P SOD1: P (in terminal mice)	ND	ND	ND	Earlier signs: 35 weeks; MN loss: %; ND; 1/3 of mice show forelimb paralysis	36	ND	Terminal mice show severe weight loss >30%. Age-dependent clinical/pathological motor abnormalities in HEM. Only 1/3 of G127X mice showed foreleg onset, but rapid disease course (7-10 days after first sign). No thioflavin-S-positive inclusions in BS or SC unlike other ALS mice.	(Jonsson et al., 2004)
SOD1 L126Z	Transgenic Promoter: hSOD1	C3H/HeJxC57BL/6J F2	hSOD1; low expression	Inclusions: P SOD1: Ab Ubiquitin: P	P	ND	ND	Earlier signs: 28-36 weeks; MN loss: %; ND; end-stage paralysis: ~39 weeks	ND	ND	ND	(Wang et al., 2005)
SOD1 L126ZdelIT	Transgenic Promoter: hSOD1	C57BL/6	hSOD1; low expression	Inclusions: P SOD1: P	P SC	P	ND	Earlier signs: 25-43 weeks; MN loss: %; ND; end-stage paralysis: P	26-45	Motor coordination impairment	ND	(Watanabe et al., 2005)
SOD1 L126Z	Transgenic Promoter: hSOD1	ND	hSOD1	Inclusions: P SOD1: P	ND	ND	ND	Earlier signs: 48 weeks; MN loss: %; ND	51-57	ND	ND	(Deng et al., 2006)
SOD1 T116X	Transgenic Promoter: hSOD1	C57BL/6xSJL	hSOD1; low expression	Inclusions: P Ubiquitin: P	P	P	ND	Earlier signs: 41 weeks; MN loss: %; ND; end-stage paralysis: P	~43	Motor coordination impairment	HEMs: no phenotype; HOMs: reported to develop ALS. Double transgenics (T116x/WT hSOD1) develop ALS phenotype; weight loss by end stage. Liver tumours, kyphosis, reduced body weight (~4 weeks). HOMs: males have significantly reduced lifespan compared with that of females.	(Han-Xiang et al., 2008)
Sod1 D93G (JAX 020440)	ENU point mutant Promoter: mSod1	C57BL/6J+C3H background to C57BL/6J	mSOD1; reduced protein levels and loss of activity	Ab	P	P	P	HOMs: Earlier signs: 15 weeks; UMN loss: ~20% by 29 weeks ~23% LMN loss: ~23% by week 15-52	~88	Motor coordination impairment	Motor coordination impairment	(Joyce et al., 2015)
(B) TDP-43 mouse models												
hTDP-43 WT (JAX 016608)	Transgenic Promoter: mPip	C57BL/6	>hTDP-43 and ~WT mTDP-43, cytotoxic ~25 kDa	Inclusions: P Ubiquitin: P	P	Ab	ND	Early signs at 3 weeks; no final MN loss	no ~4-8	Mild motor coordination impairment	HOM show severe motor deficits, brain atrophy and weight loss.	(Xu et al., 2010)
hTDP-43 WT lines 3, 4, 21 (JAX 016201)	Transgenic Promoter: mPip	Initially on mixed background (B6 SJL and CD1), now B6 SJL	Reduced hTDP-43+25-35 kDa fragments	Inclusions: P Ubiquitin: P TDP-43: co-localises with Ub	ND	P	ND	Ab	~15	ND	Some founders show aggressive motor phenotype (survival of 1-5 weeks). Later-onset lines show weakness and hypotonia. Weight loss.	(Stallings et al., 2010)
hTDP-43 WT (JAX 017907)	Transgenic Promoter: mPip	C57BL/6/C3H backcrossed with C57BL/6J	No nuclear loss of hTDP-43. Increase of hTDP-43 expression decrease of endogenous protein	Inclusions: P Ubiquitin: P TDP-43: Ab	Ab	Ab	Ab	No final MN loss	~104	No or mild motor coordination impairment	Phenotypically normal. No weight loss.	(Arnold et al., 2013; Mitchell et al., 2015)
hTDP-43 WT line W3	Transgenic Promoter: mThy1.2	C57BL/6	hTDP-43 nuclear inclusions containing FUS, SC35 (also known as SRSF2) and proteins involved in RNA metabolism	Inclusions: P Ubiquitin: P TDP-43: Ab	Ab	P	P	Early signs at ~2-12 weeks; no final MN loss	Normal	Motor coordination impairment	Phenotype more severe in males than females. Significant increase in GEM bodies in MNs.	(Shan et al., 2010)
hTDP-43 WT (JAX 012836)	Transgenic Promoter: mThy1.2	C57BL/6/ SJLxC57BL/6J	hTDP-43	HOM Inclusions: P Ubiquitin: P TDP-43: rare but co-localises with Ub	P	ND	ND	Early signs at ~2-56 weeks; significant MN loss in line TAR6/6 and 25% MN loss in line TAR4/4, end stage paralysis: P	HOM ~3 HEM ~104	Mild to severe motor coordination impairment	Progressive motor impairments with fasciculation and spasms of facial muscle. Differences in the phenotype between Tg lines.	(Wills et al., 2010)

hTDP-43 WT line W12 (JAX 016841)	Transgenic Promoter: CaMKII tTactet-off	C57BL/6JxC3H/HeJ	hTDP-43; loss of nuclear mTDP-43 and cytoplasmic hTDP-43	Inclusions: P Ubiquitin; P TDP-43; co-localises with Ub	P	Ab	ND	UMN (% MN loss: ND) ~24	Mild to no motor coordination impairment	Brain atrophy. Single Tgds express little to no hTDP-43. Degeneration of neurons in DG.	(Igaz et al., 2011)
hTDP-43 WT	Transgenic Promoter: CaMKII tTactet-off	FVBN	hTDP-43 overexpress in forebrain	Inclusions: P Ubiquitin; P TDP-43; P	P	ND	ND	Early signs at 8 weeks; no final MN loss	Motor coordination impairment	Learning and memory deficits. Disruption ERK phosphorylation, inhibition GABA neurotransmitter.	(Tsai et al., 2010)
ITDP-43 WT/dITDP-43 WT	Transgenic Promoter: CaMKII tTactet-off	FVBN/Cx12956	hTDP-43; mTDP-43 downregulated in response to overexpression of hTDP-43	Inclusions: P Ubiquitin; P Occasionally p62/TDP-43; P (ITDP-43WT) pTDP-43; P (dITDP-43WT)	P	ND	ND	Early signs at ~4 weeks No final MN loss	ND	Two mouse lines: ITDP-43 WT (expressing ITDP-43) show aggressive phenotype in early development stages. dITDP-43 WT on Dox up to 21 days show longer lifespan and slower progressive neurodegeneration.	(Cannon et al., 2012)
hTDP-43 WT	BAC transgenic Promoter: mTardbp	C3HxC57BL/6	hTDP-43 mainly in nucleus. Increased level of cytotoxic ~25 kDa C-terminal fragment of TDP-43	Ab	P	ND	P	Early sign at ~42 weeks; no final MN loss	Motor coordination impairment	Peripherin aggregates in the hippocampus. Age-associated cognitive and motor deficits.	(Swarup et al., 2011)
TDP-43 A315T/G348C	BAC transgenic Promoter: mTardbp	C3HxC57BL/6	hTDP-43; increased level of cytotoxic ~25 kDa C-terminal fragment of TDP-43	Inclusions: P Ubiquitin; P TDP-43; P	P	ND	P	Early signs at ~42 weeks; no final MN loss.	Motor coordination impairment	Peripherin aggregates in the hippocampus. Age-associated cognitive and motor deficits.	(Swarup et al., 2011)
TARDBP A315T (JAX 010700)	Transgenic Promoter: mPip	C57BL/6JxCBA then crossed with C57BL/6J by Hatzipetros et al. (2014)	hTDP-43; fragments 25-35 kDa but not in detergent-insoluble phase	Ubiquitin; P TDP-43; rare	P	P	P	Early signs at 8-12 weeks; MN loss: 20% at ~26 weeks	Motor coordination impairment	Original line on a non-congenic genetic background showed considerable neuromuscular deficits. Hatzipetros et al. (2014) backcrossed the line with C57BL/6J before starting the study. Motor phenotype confused by gut phenotype. Significant sex differences.	(Wegorzewska et al., 2009; Hatzipetros et al., 2014)
TDP-43 A315T lines 23, 27, 35, 61 (JAX 016143)	Transgenic Promoter: mPip	C57BL/Niac-P/PrC and Pep3 (also known as Pep3) alleles from SJL/J strain x CD1 then colony randomly bred to CD1 and mixed background mice	High hTDP-43+25-35 kDa fragments	Inclusions: P Ubiquitin; P TDP-43; rare pTDP-43	P	P	ND	Early signs at 2-8 weeks; no final MN loss	Mild motor coordination impairment	Later-onset progressive motor phenotype.	(Stallings et al., 2010)
TDP-43 M337V	Transgenic Promoter: mPip	C57BL/Niac-P/PrC and Pep3 alleles from SJL/J strain x CD1 then randomly bred to CD1 and mixed background	High hTDP-43+25-35 kDa fragments	Inclusions: P Ubiquitin; P TDP-43; P	P	ND	ND	~2-6	ND	Transgenic founders show aggressive motor phenotype.	(Stallings et al., 2010)
TDP-43 M337V (JAX 017604)	Transgenic Promoter: mPip	C57BL/6	hTDP-43 mainly nuclear. Dose dependent hTDP-43 and <WT mTDP-43	Inclusions: P Ubiquitin; P	P	ND	ND	~4	Motor coordination impairment	HEMs: no phenotype. HOMs: early signs at 40 weeks with brain atrophy and hyperphosphorylated Tau in cytoplasm. Weight loss.	(Xu et al., 2011)
hTDP-43 M337V	Transgenic Promoter: mPip	C57BL/6/C3H backcrossed with C57BL/6J	hTDP-43; no nuclear loss of TDP-43	Ab	Ab	Ab	Ab	Early signs at 40 weeks; age-dependent MN loss (% ND)	Motor coordination impairment	Ab	(Arnold et al., 2013)
TDP-43 M337V	Transgenic Promoter: mThy1.2	BL/6SJLxC57BL/6J	hTDP-43; different level of expression depending on the founder. Fragments 25-35 kDa. No co-localisation between TDP-43 and stress granules	Inclusions: P Ubiquitin; P TDP-43; Ab but some p62/TDP-43	P	Ab	Ab	Early signs at 1.5-56 weeks; MN loss %; ND: end-stage paralysis: ~4 weeks	Motor coordination impairment	Several founders with aggressive phenotype. Founders with milder phenotype show late onset and longer survival. Weight loss.	(Janssens et al., 2013)

Continued

Table 1. Continued

Strain name	Transgenic/gene-targeted knock-in/ENU	Genetic background	Protein	Inclusions/aggregates	Gliosis	MA/MD	NMJ loss	Final-stage disease (terminal MN loss)	Survival (weeks)	Behavioural analysis	Other phenotypes	Reference
hTDP-43 Q331K (JAX 017933)	Transgenic Promoter: mPp	C57BL/6J/C3H backcrossed with C57BL/6J	No nuclear loss of TDP-43	Ab	Ab	P	P	Early signs at 12 weeks; LMN loss: ~35-40% at 52 weeks	Normal	Motor coordination impairment	Motor deficits and muscle fibroblast. Misregulated cassette exons due to mutated TDP-43.	(Arnold et al., 2013)
hTDP-43 Q331K/low (JAX 017930)	Transgenic Promoter: mPp	C57BL/6J/C3H backcrossed with C57BL/6J	hTDP-43; no nuclear loss of TDP-43	Ab	Ab	P	P	Early signs at 40 weeks; LMN loss: ~35-40% at 52 weeks	ND	Motor coordination impairment	Motor deficits and muscle fibroblast. Misregulated cassette exons due to mutated TDP-43.	(Arnold et al., 2013)
TDP-43 Q331K (JAX 030157)	Transgenic Promoter: mPp	C57BL/6J/C3H maintained C57BL/6J background	Nuclear loss of hTDP-43. Q331K-TDP-43 mutation appears to have more tendency to aggregate in the cytoplasm	Inclusions: P Ubiquitin; P TDP-43; endogenous	P	P	P	Early signs at 3 weeks; MN loss: 70% in WT xQ331K; end-stage paralysis: by 8-10 weeks	8-10	Motor coordination impairment	Same mouse as Arnold et al., 2013, but the paper focused on double-mutant hTDP-43 WT x hTDP-43-Q331K overexpressor: No gut phenotype. Rapid disease progression. HEM Q331K line shows late-onset age-dependent motor deficit.	(Mitchell et al., 2015)
hTDP-43 ΔNLS (JAX 014650)	Transgenic Promoter: CaMKII tTactlet-off	C57BL/6J x C3H/HeJ	hTDP-43; dramatic loss nuclear WT TDP-43 and cytoplasmic hTDP-43	Inclusions: P Ubiquitin; P TDP-43; low but co-localises with Ub	Ab	Ab	ND	Early signs at 1-3 weeks off Dox; no final MN loss	~24	Motor coordination impairment	Time-dependent neurodegeneration off Dox. Single Tgs express little to no hTDP-43. Altered expression of genes e.g. <i>Tardbp</i> , <i>Hmnpa3</i> , etc.	(Igaz et al., 2011)
NEFH-ΔTA (JAX 028412)	Transgenic Crossed with hTDP-43 ΔNLS from Igaz et al., 2011 Promoter: rNEFH/ CaMKII ITR-tet-off	C57BL/6J x C3H/HeJ F1	Presence of cytoplasmic hTDP-43 ΔNLS is Dox dependent. Not found when crossed with hTDP-43 WT	Inclusions: P Ubiquitin; P TDP-43; co-localises with Ub	P	P	P	Early signs at 2 weeks off Dox; MN loss: 50% by 6 weeks off Dox	Survival 8-18 weeks off Dox and up to 20-32 weeks when Dox reintroduced	Motor coordination impairment	Dox stopped at 5 weeks. Line also crossed with hTDP-43 WT from Igaz et al., 2011 to confirm that cytoplasmic inclusions were related to ΔNLS line. Suppression of hTDP-43 ΔNLS by re-introducing Dox partially rescues phenotype. Weight loss.	(Walker et al., 2015; Spiller et al., 2018)
TDP-43 WT	Human genomic sequence targeted into <i>Rosa26</i> [Gf/(<i>ROSA26</i> /Sor)] locus in a single copy with a C-terminal Y pet fluorescent tag	C57BL/6J x C57BL/6J	hTDP-43 expression lower than endogenous mTDP-43	Ab	Ab	Ab	Ab	WT comparable with Ntg	Normal	Indistinguishable from Ntg	ND	(Gordon et al., 2019)
hTDP-43 A315T	Gene-targeted knock-in Endogenous Promoter: mTardbp	129S2/129P2/Ola x C57BL/6J 6NTac	Human cDNA gene targeted into mouse <i>Tardbp</i> locus; alteration of 3' UTR aligning importance for autoregulation	Inclusions: P Ubiquitin; P TDP-43; co-localises with Ub p62; Ab	ND	Ab	ND	Early signs at ~12-20 weeks. MN loss: 10% at 65 weeks	Normal	Mild motor coordination impairment	Pre-symptomatic model. Reduction of CD36. Altered expression of genes involved in cell death and lipid metabolism.	(Stribl et al., 2014)
TDP-43 M337V (JAX 029266)	Human genomic sequence targeted into <i>Rosa26</i> [Gf/(<i>ROSA26</i> /Sor)] locus in a single copy with a C-terminal Y pet fluorescent tag	C57BL/6J x C57BL/6J	hTDP-43 expression lower than endogenous mTDP-43	Ab	Ab	Ab	P	HOMs: early signs at ~26 weeks; symptomatic mice at ~39 weeks; no final MN loss	Normal	Motor coordination impairment	Weight reduction in male HOM. Cytoplasmic mislocalisation of hTDP-43 observed in embryonic stem cell-derived MNS.	(Gordon et al., 2019)
Tardbp Q331K (JAX 031345)	Gene-targeted knock-in Promoter: mTardbp	C57BL/6J	mTDP-43; TDP-43 GOF. 45% increase in nuclear TDP-43 in mutant, impaired autoregulation	Ab	Ab	Ab	Ab	Early signs at ~20 weeks; no final MN loss	~80	Mild to no motor coordination impairment at 20 and 24 weeks. Cognitive and memory impairment	Aberrant behaviour, hyperphagia, high weight heterogeneity. Significant expression/splicing differences in brain, SC by 20 weeks. Skipping of conserved exons.	(White et al., 2018)
Tardbp Q331K	Gene-targeted knock-in Promoter: mTardbp	C57BL/6J	mTDP-43; TDP-43 gain-of-splicing function	ND	ND	ND	ND	ND	ND	ND	ND	(Fratte et al., 2018)

Tardbp Q101X (JAX 019899)	ENU point mutant Promoter: mTardbp	C57BL/6JxC3H/HeH	mTDP-43; no difference in protein level between WT/ mutant TDP-43	Ab	Ab	Ab	Ab	Ab	Ab	ND	Early signs at 32-61 weeks; no final MN loss	Mild/no motor coordination impairment	Loss of body tone. No weight loss. Aberrant exon inclusion. HOMs: embryonic lethal. TDP43 LOF effects on expression and splicing.	(Ricketts et al., 2014) (Fratte et al., 2018)
Tardbp F21(BRC# GD000108)	ENU point mutant Promoter: mTardbp	On C57BL/6J embryonic day 18.5; viable HOM on C57BL/6J-DBA/2J	mTDP-43; TDP-43 LOF (shift towards exon inclusion), cryptic exon. Reduced RNA binding	Ab	Ab	Ab	Ab	Ab	Ab	ND	Ab	Motor coordination impairment	TPD43 GOF effects on expression and splicing.	(Fratte et al., 2018)
Tardbp M323K (BRC# GD000110)	ENU point mutant Promoter: mTardbp	On C57BL/6J embryonic lethal; viable HOM on C57BL/6J-DBA/2J	mTDP-43; TDP-43 GOF (increased exon exclusion), skipic exon. No nuclear depletion. Increased Tardbp intron 7 retention	Inclusions: P Ubiquitin; P TDP-43; Ab	ND	ND	Ab	Ab	Ab	Normal	Early signs at ~52 weeks; MN loss: 28% at 104 weeks	Motor coordination impairment		(Fratte et al., 2018)
(C) FUS mouse models														
hFUS (+/+) hFUS (+/-) (JAX 017916)	Transgenic Promoter: mPrp	C57BL/6S.JL	Diffuse cytoplasmic hFUS staining, no loss of nuclear FUS. hFUS decreases WT mFUS. Toxic GOF and dose-dependent toxicity	Inclusions: P Ubiquitin; P FUS; P	P	P	P	P	P	10-104	HOMs: MN loss: 60%; end-stage paralysis: at ~11 weeks	Motor coordination impairment	HEMs: no motor phenotype, mild MN loss and gliosis at 104 weeks. HOMs: aggressive phenotype, hind limb paralysis and rapid disease progression at 10-13 weeks. Modest reduction in α -motor axons and NMJs by 24 months.	(Mitchell et al., 2013)
hgFUS-WT line 88	BAC transgenic Promoter: hFUS	C57BL/6	Levels of hFUS similar to normal endogenous mouse levels. mFUS endogenous levels down due to auto-regulation. hFUS not overtly mislocalised	Ab	Ab	ND	Ab	Ab	Ab	Normal	Ab	Non-significant motor or cognitive abnormalities		(López-Erauskin et al., 2018)
CAG-FUS-WT (JAX 027898)	Transgenic Promoter: CAG	CAG-Z-FUS-IRES-EGFPWT mice are C57BL6/CR CAG-Z-FUS-IRES-EGFPWT crossed with Meox2-Cre mice (129S4/ SvJaexC57BL6) to create CAG-FUSWT	High levels of cytoplasmic hFUS	Ab	Ab	ND	Ab	Ab	Ab	2-4	Early signs at ~34 weeks; no final MN loss	Motor coordination impairment	100% of the CAG-FUS_WT die at less than postnatal day 30. Significant body weight loss. Altered gene expression.	(Septon et al., 2014)
hFUS-WT (JAX 020783)	Transgenic Promoter: mPrp	C57BL/6xS.JL F2 then C57BL/6	hFUS	Ab	Ab	ND	Ab	Ab	Ab	~30	Early signs at ~34 weeks; no final MN loss	Motor coordination impairment		(Tishirani et al., 2015)
hFUS-R465X (JAX 019728)	Transgenic Promoter: mPrp	C57BL/6xS.JL F2 then C57BL/6	High levels of cytoplasmic hFUS	Ab	Ab	ND	Ab	Ab	Ab	Some HEM ~17HOM ~8. Average shows normal survival	Early signs at ~34 weeks; no final MN loss	Motor coordination impairment	Some HEM died prematurely due to intestinal swelling. Decrease in transcriptional activity inside neurons. Age-dependent loss of α -motor axons. Synapsis alterations. Altered gene expression.	(Tishirani et al., 2015)
hgFUS-R521C line 10	BAC transgenic Promoter: hFUS	C57BL/6	Levels of hFUS similar to normal endogenous mouse levels. mFUS endogenous levels down due to auto-regulation. Level of hFUS-R521C in brain and SC similar to endogenous FUS. Levels of endogenous FUS seem to be increased	Ab	Ab	ND	Ab	Ab	Ab	Normal	Mild MN degeneration by 24 months	Motor coordination impairment. Loss of grip strength starting by 8 months. Progressive cognitive impairment. Motor coordination impairment	Increased γ -H2AX levels in cortex and SC (Chat*). Increased ATF3 indicating increased DNA damage. Severe impairment in BDNF-TRK signalling.	(Qiu et al., 2014)
FUS-R521C (Flag tagged) (JAX 026406)	Transgenic Promoter: Syrian hamster prion (ShPrP)	C57BL/6 S.JLxC57BL/6	Levels of hFUS similar to normal endogenous mouse levels. mFUS endogenous levels down due to auto-regulation. hFUS-R521G not overtly mislocalised	Inclusions: P Ubiquitin; ND FUS; P	P	P	P	P	P	HEM 23-46	Early signs at 5-14 weeks; MN loss: HEM >50% at 4-12 weeks	Motor coordination impairment	Age-dependent loss of α -motor axons. Synapsis alterations. Altered gene expression.	(López-Erauskin et al., 2018)
hgFUS-R521H line 9	BAC transgenic Promoter: hFUS	C57BL/6	Levels of hFUS similar to normal endogenous mouse levels. mFUS endogenous levels down due to auto-regulation. hFUS-R521G not overtly mislocalised	Ab	Ab	ND	Ab	Ab	Ab	Normal	Mild MN degeneration by 24 months	Motor coordination impairment. Loss of grip strength starting by 8 months. Progressive cognitive impairment	Age-dependent loss of α -motor axons. Synapsis alterations. Altered gene expression.	(López-Erauskin et al., 2018)
CAG-FUS-R521G (JAX 028021)	Transgenic Promoter: CAG	CAG-Z-FUS-IRES-EGFP-R521G mice are C57BL6/ICR CAG-Z-FUS-IRES-EGFP-R521G crossed with Meox2-Cre mice (129S4/ SvJaexC57BL6)	hFUS-R521G not overtly mislocalised	Ab	Ab	P	Ab	Ab	Ab	50-70% die at <4 weeks; remaining 30-50% reach adulthood	Ab but alteration in dendritic branches observed in CAG-FUSR521G UMN and LMN	severe motor, coordination impairment. In the remaining 30-50%: moderate motor, coordination impairment	In the 50-70% that die early: similar to CAG-FUSWT but no altered gene expression. In the remaining 30-50%: reduced body weight, impairments in sociability, impaired forelimbs, reduction in locomotion	(Septon et al., 2014)

Continued

Table 1. Continued

Strain name	Transgenic/gene-targeted knock-in/ENU	Genetic background	Protein	Inclusions/aggregates	Gliosis	MA/MD	NMJ loss	Final-stage disease (terminal MN loss)	Survival (weeks)	Behavioural analysis	Other phenotypes	Reference
ΔNLS-hFUS (myc-tagged)	Transgenic Promoter: mThy1.2	to create CAG-FUSR21G BDF1×C57BL/6	Cytoplasmic hFUS	Inclusions: P Ubiquitin; P G3BP protein; P	P (FC)	ND	ND	Early signs at 12 weeks; no final MN loss	~60	Motor coordination impairment	activities but no altered gene expression. Reduced GEM numbers in cortex, but no MN loss. Age-dependent phenotype.	(Shihashi et al., 2016)
Fus/NLS/+Fus/NLS/ΔNLS	Gene targeted Promoter: mFUS	C57BL/6. Also crossed with Chat-Cre line (129S6/SVEvTac)	mFUS; increase of ADMA-FUS in cytoplasm and nucleus	Inclusions: no large Ubiquitin; P Chat-Cre line p62; Ab	P	ND	P	Early signs at ~40 weeks; HET: ~88%; HOM: neonatal lethality	HET: ~88%; HOM: neonatal lethality	Motor coordination impairment	Mice crossed with Chat-Cre mice show delayed MN degeneration. Alteration of genes involved in myelination and in several FUS binding partners. Defects in Schwann cells.	(Seokic-Zahirovic et al., 2016; 2017)
ΔOFF/ONhFUS-P525L	Gene targeted into the Mapt locus. Promoter: mMapt (silent until activated by Cre-mediated recombination)	Ola1/129/C57BL/6J	hFUS; endogenous mFUS in nucleus, no significant change in expression of mFUS and mTau in HET. No interaction between mFUS and hFUS. Possible toxic GOF of hFUS	Inclusions: no large Ubiquitin; Ab FUS: cytoplasmic localisation	P	P	P	Early signs at ~4 weeks; MN loss: progressive, 23.6% at ~52 weeks	ND	ND	hFUS WT line created as control (no phenotype). Crossed	(Sharma et al., 2016)
ΔOFF/ONhFUS-R521C	Gene targeted into the Mapt locus. Promoter: mMapt (silent until activated by Cre-mediated recombination)	Ola1/129/C57BL/6J	hFUS; endogenous mFUS in nucleus, no significant change in expression of mFUS and mTau in HET. No interaction between mFUS and hFUS. Possible toxic GOF of hFUS	Inclusions: no large Ubiquitin; Ab FUS: cytoplasmic localisation	P	P	P	Early signs at ~8 weeks; MN loss: progressive, 18.6% at ~52 weeks	ND	Mild motor coordination impairment	hFUS WT line created as control with no phenotype. Crossed	(Sharma et al., 2016)
FUSΔE14 (EMMA EM:11106)	Gene targeted and partial humanisation Promoter: mFUS	C57BL/6N/C57BL/6J	m/hFUS; mislocalisation of FUSΔE14. Equivalent endogenous level of FUS protein in both WT and FUSΔE14	Ab	ND	ND	P	Early signs at 48 weeks; MN loss: 20% at 78 weeks	<88	Mild motor coordination impairment	Toxic GOF of mutant FUS. Recruitment of mutant FUS into SG observed in fibroblasts of both human/mice carrying FUSΔE14 mutation. Altered expression of genes encoding mitochondrial/ribosomal proteins.	(Devoy et al., 2017)
(D) UBQLN2 mouse models												
UBQLN2 WT line 358	Transgenic Promoter: mThy 1.2	C57BL/6C3/C57BL/6J. Then crossed with C57BL/6J	HUBQLN2; low overexpression of human UBQLN2	Ab	Variable	Ab	Ab	No final MN loss	ND	No motor coordination impairment	Diffuse TDP-43 in nucleus rather than cytoplasm. Mild neuron loss in hippocampus – toxicity.	(Le et al., 2016)
UBQLN2 WT line 356 (JAX 029970)	Transgenic Promoter: mThy 1.2	C57BL/6C3/C57BL/6J. Then crossed with C57BL/6J	HUBQLN2; high overexpression of human UBQLN2	Ab	Variable	Ab	Ab	No final MN loss	ND	No motor coordination impairment	Diffuse TDP-43 in nucleus rather than cytoplasm. Mild neuron loss in hippocampus – toxicity.	(Le et al., 2016)
UBQLN2 P497H	Transgenic Promoter: hUBQLN2	C57BL/6×S-JL cross	Similar expression level hUBQLN2 P497H and mouse protein. Mutated protein binds proteasome and substrates, affecting the clearance of ubiquitinated proteins	Inclusions: P Ubiquitin; P p62; P UBQLN2; P OPTN; P TDP-43; Ab	ND	ND	ND	Earlier signs: ~4 weeks; no final MN loss	~70	Mild cognitive and temporal memory but no motor coordination impairment	Observed 'dendritic sprouting' with protein inclusions (dendritic spines). Transgene on Y chromosome so only male mice.	(Gorne et al., 2014)
UBQLN2 P497S_3/029966 029969)	Transgenic Promoter: mThy 1.2	C57BL/6C3/C57BL/6J. Then crossed with C57BL/6J	Increased with age endogenous UBQLN2 at the end stage	Inclusions: P Ubiquitin; P Thioflavin S; P TDP-43; P	P	P	P	Earlier signs: ~4 weeks; MN loss: 20% for P497S_3 and 15% for P506T_6 at ~34 weeks	~35/43	Motor coordination impairment and mild memory deficits	Reduction of nuclear TDP-43 and TDP-43* clusters in cytoplasm; sometimes co-localised with UBQLN2. Loss of neurons in hippocampus.	(Le et al., 2016)

UBQLN2 P520T	Gene targeted Promoter: mUbqln2	C57BL/6JIN Tac	mUBQLN2; observed reduced binding of mutant UBQLN2 to HSP70	Inclusions: P Ubiquitin: P	ND	ND	ND	ND	Earlier signs: ~39 weeks; no final MN loss	Cognitive but no motor coordination impairment.	UBQLN2-P520xR6/2 showed increased HTT, which co-localised with UBQLN2 due to its LOF.	(Hjerpe et al., 2016)
(E) VAPB mouse models												
hVAPB WT	Transgenic (with IRES-EGFP reporter cloned after STOP codon VAPB) Promoter: mThy 1.2	C57BL/6-C57BL/6	hVAPB; increased expression	Ab	ND	ND	ND	ND	No final MN loss	No significant differences between hVAPB WT and Nig	ND	(Alaiga et al., 2013)
hVAPB P56S	Transgenic (with IRES-EGFP reporter cloned after STOP codon VAPB) Promoter: mThy 1.2	C57BL/6-C57BL/6	hVAPB; increased expression but significantly less protein compared with hVAPB WT	Inclusions: P Ubiquitin: P VAPB:P p62: P	ND	ND	ND	ND	Earlier signs: ~9-52 weeks; MN loss: 60% at 78 weeks	Mild motor coordination impairment	C-bouton-mediated muscarinic receptor function significantly compromised.	(Alaiga et al., 2013)
Vapb P56S (JAX 028360)	Gene targeted Promoter: mVapb	C57BL/6-C57BL/6Nc1	m/vapb; similar levels as WT (less protein in HOM than HET). VAPB translocated from ER to autophagosome	Inclusions: P Ubiquitin: P VAPB:P	ND	Mild	Mild	ND	Earlier signs: ~48 weeks; no final MN loss	Mild motor coordination impairment	Age-dependent ER stress.	(Larroquette et al., 2015)
(F) VCP mouse models												
hVCP-R155H	Transgenic (p97/VCP-WT) Promoter: muscle creatine kinase (mMCK)	C57BL/6	hVCP	Inclusions: P Ubiquitin: P VCP: Ab	ND	P	ND	ND	Earlier signs: ~24 weeks; no final MN loss	Mild motor coordination impairment	ND	(Weihi et al., 2007)
hVCP-R155H	Transgenic (CMV-enhanced chicken β -actin)	SJLxC57/C57BL/6	hVCP	Inclusions: Ab Ubiquitin: P TDP-43: P	Mild	P	ND	ND	Earlier signs: ~12 weeks; no final MN loss	Motor coordination impairment	Progressive muscle weakness. Severe osteopenia (focal lytic and sclerotic lesions).	(Custer et al., 2010)
hVCP-A232E	Transgenic (CMV-enhanced chicken β -actin)	SJLxC57/C57BL/6	hVCP	Inclusions: Ab Ubiquitin: P TDP-43: P	Mild	P	ND	ND	Earlier signs: ~12 weeks; no final MN loss	Motor coordination impairment, emotional and cognitive impairment	Progressive muscle weakness. Severe osteopenia (focal lytic and sclerotic lesions).	(Custer et al., 2010)
Vcp R155H (JAX 021968)	Gene targeted Promoter: mVcp	129/SVEVxC57BL/6JEJ (backcrossed >6x to be >98% C57BL/6)	mVcp	Inclusions: P Ubiquitin: P VCP: Ab in muscle but P in frontal cortex TDP-43: P	Ab	ND	ND	ND	Earlier signs: ~12 weeks; no final MN loss	Motor coordination impairment	Increased cortical wall thickness, vacuoles in muscle and seizures. Mouse initially used to study Paget's disease.	(Badadani et al., 2010)
Vcp R155H	Gene targeted Promoter: mVcp	129/SVEVxC57BL/6JEJ (backcrossed >6x to be >98% C57BL/6)	mVcp	Inclusions: P Ubiquitin: P	P	ND	ND	ND	Earlier signs: ~39 weeks; MN loss: 50% at ~86 weeks	Motor coordination impairment	Same model as Badadani et al. (2010) but without Neo cassette. Late onset. Similar brain, muscle and bone pathology as Badadani et al. (2010).	(Yin et al., 2012)
Vcp R155H	Gene targeted Promoter: mVcp	129/SVEVxC57BL/6JEJ (backcrossed >6x to be >98% C57BL/6)	mVcp	Inclusions: P Ubiquitin: P TDP-43: P VCP: Ab	P	P	P	P	Mild/progressive weakness at ~69 weeks	Motor coordination impairment	Widespread acute denervation and accelerated muscle/SC pathology. Prominent myopathic changes. Increased autophagy. Fewer HOMs than expected with Mendelian ratio.	(Nalbandian et al., 2013, 2012)

Ab, phenotype is stated as absent; BS, brain stem; CMV, cytomegalovirus; CNS, central nervous system; DC, dentate gyrus; Dox, doxycycline; FC, frontal cortex; GEM, Gemini of coiled bodies; GOF, gain of function; h (before gene/promoter/protein), human; HEM, hemizygous; HET, heterozygous; HOM, homozygous; LMN, lower motor neuron; LOF, loss of function; m (before gene/promoter/protein), mouse; MA, muscle atrophy; MD, muscle degeneration; MN, motor neuron; ND, phenotype has not been determined; NMJ, neuromuscular junction; Nig, non-transgenic littermates; P, phenotype is present (see references listed in table); p, phosphorylated; SC, spinal cord; SG, stress granules; Tg, transgenic; Ub, ubiquitin; UMN, upper motor neuron; WT, wild type. All the phenotypes described on the genetic background indicated.

In contrast, only one of the published *UBQLN2* transgenic lines, carrying the P497S mutation, which disturbs proteasomal degradation, shows motor impairment, mild MN loss (20%) and cytoplasmic aggregates positive for ubiquitin and TDP-43 (Le et al., 2016) (Table 1D). The only mouse model expressing a mutated VAPB protein has a progressive phenotype resulting in ~60% MN loss by 78 weeks of age (Aliaga et al., 2013) (Table 1E), whereas results are mixed for the VCP transgenic models (Table 1F). Despite the variability in phenotype presentation, transgenic mice remain a critical resource for understanding neurodegeneration but, like all mouse models, they have generic characteristics we need to take into account, as discussed below.

Site of insertion

Transgene DNA is usually microinjected into fertilised eggs and randomly inserts into the host mouse genome. This can lead to insertional mutagenesis from disrupting a host gene, producing an aberrant phenotype, which is why multiple founder lines from independent transgenic embryos are studied – to be confident that the common phenotypes arise from the transgene. Almost all transgenic lines in Table 1 do not have information on the insertion site, as is the case for the vast majority of transgenic models of neurodegenerative disease (Tosh et al., 2017; Goodwin et al., 2017). Fortunately, in *SOD1^{G93A}* mice, the transgene insertion site does not disrupt a known gene (Srivastava et al., 2014; Achilli et al., 2005).

Transgene copy number and gene expression

Transgenic DNA tends to concatemerise as it inserts into the genome, leading to multiple copies of the exogenous sequence. This results in the overexpression of the protein of interest, often leading to accelerated phenotypes. Furthermore, a caveat to studying transgenic mice arises from the development of aberrant phenotypes due to overexpression. The *SOD1^{G93A}* model used most commonly carries ~25 copies of the human transgene, resulting in overexpression of the protein (Gurney et al., 1994; Shibata, 2001), with MN degeneration progressing rapidly: disease onset occurs at ~90 days and the humane endpoint occurs by ~130 days of age, depending on the genetic background of the mouse. However, transgenic mice expressing wild-type human SOD1 at a similar level to mice expressing the mutant transgene have neurological phenotypes likely arising from overexpression and not from mutation, including spinal cord vacuolation with early signs of paresis in one or more limbs (Jaarsma et al., 2000) and even MN loss (Graffmo et al., 2013). Thus, the ideal controls for mutant transgenic mice are transgenic animals expressing the wild-type transgene at similar levels to the mutant mice to control for the effects of overexpression per se. However, the wild-type human SOD1 transgenic lines are not without problems. For example, transgene insertion sites have not been assessed, and although they develop phenotypes relevant to MN disease, these are more profound in some of the mutant SOD1 transgenic lines, such as the *SOD1^{G93A}* model. Nevertheless, a large proportion of ALS studies in mutant transgenic mice do not use wild-type transgenic controls, and this is an option that should at least be considered for future work.

Some genes are highly dosage sensitive and a subtle deviation from the physiological levels leads to aberrant phenotypes, even when the protein product is wild type. Many of the RNA-binding proteins that cause ALS when mutated belong to this category, including TDP-43 and FUS (Table 1B,C). For example, transgenic mice overexpressing wild-type human *TARDBP* (from a Thy1.2 promoter) by 1.2× to 2× fold over the endogenous gene level have 25% MN loss with rare cytoplasmic inclusions containing TDP-43

(Wils et al., 2010). Overexpression of human wild-type *FUS* (under the mouse prion promoter) results in aggregation of human FUS protein and 60% loss of MNs in homozygous transgenic mice, leading to a more severe phenotype in homozygotes than in hemizygotes (Mitchell et al., 2013) (Table 1C). Indeed, RNA-binding proteins such as TDP-43 often control the expression levels of their own transcript through autoregulation. Therefore, when transgene expression levels of wild-type or mutant proteins rise above a threshold, the expression levels of the mouse endogenous transcripts are reduced, possibly contributing towards toxicity.

Furthermore, transgenes are often engineered to have exogenous promoters to ensure high levels of expression in the tissues of interest, but such ectopic expression can result in novel phenotypes. For example, two unrelated transgenic mouse lines overexpressing VCP with the R155H mutation, under the control of a muscle creatine kinase (mMCK) or a cytomegalovirus (CMV) promoter, have differences in the survival and presence of cytoplasmic aggregates containing VCP, and variability in the levels of motor impairment (Table 1F) (Weihl et al., 2007; Custer et al., 2010). Similarly, transgenic mice overexpressing mutant human *TARDBP^{A315T}* driven by the mouse prion promoter (the activity of which is strong in neurons, although it is also widely expressed in other cell types) unexpectedly die early from neurodegeneration in the gut rather than in MNs (Wegorzewska et al., 2009; Hatzipetros et al., 2014).

Finally, the transgene array may alter copy number at meiosis; thus, colonies need to be monitored constantly because the transgene's copy number usually determines phenotype severity. For example, the Tg(*SOD1**G93Adl)1Gur (*SOD1G93Adl*; also known as G1del) mice appear to have arisen from a deletion in the transgene array of a *SOD1^{G93A}* mouse (<http://jaxmice.jax.org/strain/002300.html>). The resulting 'low copy' *SOD1^{G93A}* transgenic mouse strain carries ~8-10 copies of the human *SOD1G93A* transgene instead of the ~25 in the progenitor line, and these 'low copy' animals develop paralysis between 24 and 34 weeks of age, considerably later than the 'high copy' progenitor line (Alexander et al., 2004; Acevedo-Arozena et al., 2011).

BAC transgenic mice

Most – but not all transgenic animals – have been made with the longest known complementary DNA (cDNA) sequence for the gene of interest; this is usually because of constraints on DNA insert size in the plasmid vectors used to subclone the transgenic constructs. To avoid this size limit and to generate mice carrying the full genomic architecture of a gene (which is particularly important in the case of *C9ORF72*-ALS, for which the mutation is intronic), researchers can generate transgenic mice with bacterial artificial chromosome (BAC) vectors, which can carry inserts of up to ~200 kb. This approach was used to generate, for example, *C9ORF72* (Balendra and Isaacs, 2018), TDP-43 (Swarup et al., 2011) and FUS (López-Erauskin et al., 2018) BAC transgenic mice. BACs randomly insert into the mouse genome, but generally with very low copy numbers (one to three copies), limiting the effects of overexpression of the gene of interest, although even subtle overexpression can alter the phenotype. As with all transgenics, there is the undesired possibility of insertion mutagenesis, in which integration of the transgene can disrupt an important gene.

Generic transgenic mouse features for ALS research

Until recently, transgenics were the fastest technology to obtain genetically modified mice, but this is changing as CRISPR/Cas9-based technologies develop. As discussed above, phenotypes can be rapid and severe in transgenic models because of expression of the

transgene above endogenous levels. This is helpful for understanding the advanced stages of disease, which in the natural history of ALS is comparable to when most patients receive the diagnosis. Several transgenic models can have quantifiable, progressive loss of MNs severe enough to lead to profound locomotion defects and paralysis during the mouse lifespan (Table 1). These features made them the models of choice for pre-clinical studies and, until recently, almost all ALS therapeutics were solely tested on SOD1 transgenic models. This provides some explanation for the past failures of translating promising therapeutics from SOD1 transgenics to ALS patients, 98% of whom do not suffer from *SOD1*-ALS (Urushitani et al., 2007; Turner and Talbot, 2008; Riboldi et al., 2011; Vallarola et al., 2018).

Mouse models with mutations at physiological levels in endogenous genes

Gene-targeted and ENU mutant strains

Mouse models of ALS can be generated by mutating mouse gene orthologues, to express the relevant protein at physiological levels. Here, we discuss the two key types of model with mutations in endogenous genes, produced from gene-targeting strategies or by random mutagenesis with the chemical *N*-ethyl-*N*-nitrosourea (ENU). We describe both as ‘physiological’ models in this article, as ‘knock-in’ (KI) is generally used for gene-targeted mice because it implies purposely engineering the mouse genome.

Gene-targeted models of ALS

Gene targeting entails introducing specific changes to a DNA sequence of interest. In mice, perhaps its most common use has been to create knockout (KO) animals in which the gene no longer functions, usually to help us understand the biology of individual genes. For example, the International Mouse Knockout program aims to functionally KO each mouse gene, providing phenotypic data for each KO line under the International Mouse Phenotyping program (Muñoz-Fuentes et al., 2018).

Gene KOs

Although most forms of ALS appear to be caused by toxic dominant GOF, KO models are an important resource as they can reveal not only critical gene function but also whether there is a loss-of-function (LOF) component to disease pathogenesis. For example, TDP-43 is usually depleted from the nucleus of MNs in TDP-43-ALS, presumably leading to a loss of nuclear TDP-43 function. Although homozygous TDP-43 KO mice are not viable, and heterozygous KO mice express a normal amount of TDP-43 protein due to its autoregulation, conditional TDP-43 KO lines and a transgenic line expressing small interfering RNA against TDP-43 develop MN degeneration (Kraemer et al., 2010), showing that acute TDP-43 LOF can be a driver of neurodegeneration. In *SOD1*-ALS, LOF can play a role in disease pathogenesis, as *Sod1* KO mice develop a severe peripheral neuropathy, leading to denervation (Fischer et al., 2011) and *SOD1*-ALS patients generally have diminished SOD1 dismutase activity (Saccon et al., 2013).

KI mutations

Gene targeting has been used to insert specific mutations, usually (but not always; see Sharma et al., 2016; Gordon et al., 2019) into the endogenous mouse gene, with the aim of maintaining physiological expression levels of the (mutant) protein. This approach has been used thus far for *Fus*, *Tardbp*, *Vapb*, *Vcp* and *Ubp1n2* mutations.

Classical gene targeting involves creating recombinant vectors for homologous recombination in mouse embryonic stem cells,

which can be time-consuming and relatively expensive. However, CRISPR/Cas9 targeting in zygotes has made the production of gene-targeted mice – for example, such as two recently described strains recapitulating the human *TARDBP* Q331K mutation (Fratta et al., 2018; White et al., 2018) – considerably more efficient, faster and cheaper. Nevertheless, the possible off-target effects of this technology must be taken into account (Zhang et al., 2015).

One of the first KIs to model ALS was the *Vcp*^{R155H} strain (Badadani et al., 2010; Yin et al., 2012). These mice have age-dependent degeneration of ventral horn MNs with up to 50% MN loss, TDP-43-positive cytoplasmic inclusions, mitochondrial aggregation and progressive astrogliosis. These and other *Vcp* KI mice do not have rapidly progressive fatal ALS features, but they are important for understanding the onset of ALS (Table 1F).

Site-directed insertion of exogenous DNA into known ‘safe harbour’ sites in the genome, such as the *Rosa26* locus, also uses homologous recombination and is an alternative that avoids the random insertion mutagenesis of transgenic approaches. For example, TDP-43 KI mice have been generated by inserting the complete human *TARDBP* gene from a BAC, including introns and regulatory elements, into the *Rosa26* locus. These mice show low levels of human TDP-43 expression compared with their endogenous TDP-43, absence of inclusions or gliosis, and a mild age-dependent motor dysfunction, which may give insight into early-stage disease (Gordon et al., 2019).

Genomic humanisation

Gene targeting, by homologous recombination or CRISPR/Cas9, enables us to make complex changes in mouse genes, including knocking in human genomic loci that carry important sequences for understanding disease and using these to completely replace the endogenous mouse genes. The *FUS*Δ14 KI heterozygous mice, expressing a partially humanised mutant *FUS* gene, carrying a splice acceptor site mutation that results in a frameshift that causes an aggressive form of ALS in humans, show progressive spinal MN loss, cytoplasmic mislocalisation of FUS and impaired lipid metabolism (Devoy et al., 2017) (Table 1C). An interesting avenue yet to be explored is the full humanisation of ALS genes. The biochemistry of human proteins, such as SOD1, is sometimes different from that of mouse orthologues, which could be relevant for disease modelling (Prudencio et al., 2009; Karch and Borchelt, 2010; Seetharaman et al., 2010). However, full humanisation of a gene in the context of the mouse genome remains technically challenging and may lead to artefactual results arising from altering the mouse cellular pathways. Thus, each model will have to be assessed carefully on a case-by-case basis and with wild-type human gene controls.

Generic gene-targeted mutant mouse features for ALS research

Gene-targeted models express the gene of interest at physiological levels and more closely recapitulate the human ALS-causing mutations at both the genetic and biochemical levels. Together with transgenic models, they can also advance our understanding of disease pathomechanisms, as the technology allows the development of inducible or conditional models that dissect the timing and cell specificity of disease processes. For example, *FUS*ΔNLS mice express a truncated FUS protein lacking the nuclear localisation signal (NLS), with floxed exons 13 and 14 followed by stop codons and a polyadenylation signal, allowing Cre-mediated reversal of the MN loss phenotype, giving new insight into the potential effects of ALS therapies at different disease stages (Scekic-Zahirovic et al., 2016) (Table 1C). However, although few ALS KI models have been

produced so far, as is clear from Table 1, the phenotypes of KI mice are often mild and progress slowly. For example, KI models of mutant *Vapb* and *Ubqln2* do not show strong, overt ALS features (Table 1D, F). Nevertheless, they are likely essential for understanding disease onset and the very earliest pathogenic mechanisms, and for developing important biomarkers.

Random chemical mutagenesis

Random mutagenesis of the mouse genome can give unexpected insight into human biology. Although other methods exist, such as the use of viral integration or radiation treatment, the majority of such mutant mouse models described in the literature come from the use of the powerful chemical mutagen ENU (Acevedo-Aroza et al., 2008). Typically, male mice are injected with ENU, left for several weeks until they start to produce mutant sperm and then mated to wild-type females. Their progeny, carrying point mutations, are assessed for phenotype in a forward genetics screen using wide-ranging tests, so that researchers interested in, for example, progressive locomotor mutants, may determine the causative point mutation and explore the underlying mechanism (Potter et al., 2016). This experimental design is also known as a ‘phenotype screen’. In parallel, sperm and DNA from male progeny are banked for ‘genotype screens’, in which researchers assay the DNA (usually tens of thousands of samples from a single large ENU program) for point mutations in their gene of interest. The corresponding stored sperm samples are then used for *in vitro* fertilisation to (re)derive the relevant mouse line (Stottmann and Beier, 2014).

An informative example of an ENU mutant for ALS research was identified in a genotype screen of *Sod1* within a DNA bank at the mouse facility at MRC Harwell in the UK (Table 1A). This strain, on a C57BL/6J background, carries a *Sod1*^{D83G} mutation that is orthologous to the human *SOD1*^{D83G} fALS mutation. Heterozygous animals only start to show mild locomotor effects at ~88 weeks of age, but homozygous mutant mice have a striking phenotype that has allowed the separation of *Sod1* LOF acting in the periphery and GOF effects in MN soma arising from mutant mouse Sod1 (Joyce et al., 2015).

Generic ENU mutant mouse features for ALS research

Depending on the dose of ENU, the progeny will have multiple mutations within their genome, not just in the gene of interest. Thus, these animals must be backcrossed for several generations to segregate away other mutations, and the flanking congenic region must be carefully assessed to avoid any confounding effects of nearby point mutations (Keays et al., 2007).

One of the advantages of working with ENU mice is the possibility of unexpected insights from novel mutations. However, a disadvantage is that a mutation identified in a genotype screen may not guarantee an aberrant phenotype. For example, our own group identified mouse samples with ENU-induced point mutations in *Tardbp*, but extensive assessment of a rederived strain with a truncated TDP-43 (carrying a *Tardbp*^{Q101X} mutation) revealed only limited phenotypes (Ricketts et al., 2014). Nevertheless, as our knowledge of the biochemistry and structure of ALS proteins improves, we can parse ENU mutants by protein domain to help decide which mice to rederive for study. Thus, in follow-up work, our group went on to investigate two more *Tardbp* mutants, one carrying a mutation (M323K) within the low complexity domain (LCD), and the other with a mutation (F210I) in the second RNA-binding domain (RRM2) of TDP-43. The LCD mutation results in a progressive loss of spinal MNs, whereas the RRM2 mutation

behaves as a LOF. Importantly for ALS research, transcriptomic analysis of these mice showed that C-terminal TDP-43 mutations lead to a TDP-43 gain-of-splicing function when mutations are expressed at physiological levels. This mutant TDP-43 GOF affects the splicing of a subset of genes not previously known to be controlled by TDP-43, leading to the appearance of new exon exclusion events called ‘skiptic exons’ that are, at least partially, also present in human TDP-43-ALS fibroblast cells (Fratta et al., 2018) (Table 1b).

The TDP-43 ENU mutants highlight another property of ENU mutagenesis: using this method it is relatively straightforward to generate allelic series of animals that may help us dissect protein function.

Transgenic compared with gene-targeted and ENU mouse models for ALS research

Mice and humans are different animals, and we should not expect a single mouse model to fully recapitulate the entire trajectory of human neurodegenerative disease. We have summarised the key features of two generic types of mouse model – transgenic animals and those that express the gene/mutation of interest at physiological levels – looking at the ease of making each model, and at the types of phenotypes they develop, which usually vary largely because of different expression levels of the gene of interest.

For ALS alleles with dominant modes of inheritance, or where researchers wish to alter protein structure to help dissect function, we have a choice of the type of model to study, and each generic model has different applications (Table 1). Physiological models (gene-targeted and ENU models) have slower progression of phenotypes, which are less severe than in transgenic mice, presumably because proteins are not being overexpressed. However, they maintain correct spatial and temporal levels of expression, which is crucial to avoid the dose-dependent toxicity of some proteins, allowing the study of interactions between the gene/protein of interest and its partners within a pathway over the animal’s life span. Moreover, the late disease onset in these mice is useful for gaining insight into the pre-symptomatic stages, and to identify early biomarkers. However, slow phenotypes make these animals expensive to study, as statistically significant differences from their wild-type littermates may only arise after a year or more of life, incurring significant husbandry costs. Nevertheless, they provide a wide window onto early-stage disease processes. In contrast, transgenic animals tend to express strong phenotypes and clear MN loss, making them potentially more relevant to end-stage processes. These differences are exemplified by *Vapb* and *Ubqln2* KI models that have been valuable to study potentially impaired autophagy and proteasomal degradation mechanisms in ALS pathogenesis, but which do not develop the motor impairment or MN loss that can arise in their transgenic counterparts (Table 1D,E).

Mice carrying the TDP-43 Q331K fALS mutation (Table 1B) offer another comparison between gene-targeted KI and transgenic strains. *Tardbp*^{Q331K} KIs model the toxic TDP-43 GOF, providing insight into the splicing alteration and the protein autoregulation impairment while reproducing aspects of frontotemporal dementia, although they do not show TDP-43 inclusions or MN loss (White et al., 2018; Fratta et al., 2018). In contrast, the TDP-43 Q331K transgenic line, with transgene expression driven by the mouse prion promoter, shows MN loss, muscle degeneration and neuromuscular junction loss with motor impairments, but only when the transgene is overexpressed above a threshold, confirming the dose-dependent toxic effects of TDP-43 expression (Arnold et al., 2013). Other conditional transgenic lines, such as

hTDP-43 Δ NLS mice devoid of the TDP-43 NLS, model the toxicity caused by cytoplasmic accumulation and nuclear depletion of TDP-43 (Igaz et al., 2011) (Table 1B).

In summary, several different types of mouse model have been developed worldwide with the aim of reproducing ALS-like phenotypes for functional dissection (Table 1), and it is clear that having access to both transgenic and endogenous mice for each ALS gene could help build a comprehensive picture of the effects of different human ALS mutations.

Making use of all available ALS-related mouse strains

ALS is probably not a single disease, but arises sporadically and from mutations in a number of genes with varied functions. Mouse models can help us to unravel this complex picture by comparing phenotypes across ALS gene models (Fig. 1). For example, rNLS8 mice, a transgenic model expressing cytoplasmic TDP-43, showed that reactive microglia have an important role in rescuing MN degeneration caused by cytoplasmic TDP-43 expression (Spiller et al., 2018). This is in contrast to *SOD1*^{G93A} transgenics, in which transplant of wild-type microglia significantly delays MN degeneration (Wu et al., 2006; Beers et al., 2006). These contrasting results highlight that there are specific disease trajectories in different mouse models, which is also likely the case in ALS patients. Therefore, moving forward, it will be critical to use a variety of models (mouse and other) to understand ALS pathogenesis more broadly, and there remains a need for more models for different ALS genes.

What is a good mouse model?

This brings us to a key question: what is a good mouse model? The short answer is the animal that is most informative for the underlying biology/disease under study. However, a more considered answer is that researchers must first define the features they are interested in, then chose the most appropriate model. Or better, choose different models to study the disease as broadly as possible. For example, are we looking for subtle, early molecular changes in spinal MNs, or are we interested in models with upper and lower MN death, or are we focusing on the role of glia?

There are many other factors to obtaining a useful mouse model and here we have discussed just one aspect – albeit the crucial one – of model design, i.e. how was the model generated. However, a mouse model's phenotype also depends on the same factors as in humans, including sex and genetic background, which can have profound effects on how a mutation manifests. This is why we have been careful to include these descriptors in Table 1 (Bruijn et al., 2004; Heiman-Patterson et al., 2011; Mancuso et al., 2012; Nardo et al., 2013). Similarly, the environment can markedly affect disease manifestation; for example, environmental enrichment (such as running wheels and nesting material) can increase the life span and behavioural performance in *SOD1*-G93A mice (Sorrells et al., 2009). Conversely, single housing is a cause of stress in mice and can lead to decreased life span (Kalliokoski et al., 2014), whereas good physical and social interactions positively affect animal welfare (Sundberg and Schofield, 2018).

Mouse models remain necessary for studying ALS, which is a collection of diseases that are not – as far as we know – cell autonomous and that involve different systems, including the immune system. Animal models provide a complex *in vivo* environment of tissues and cell–cell interactions, which are fundamental for the study of complex neurodegenerative diseases, such as ALS, in which the interactions between glia, MNs and muscle are likely necessary for disease development.

The final word

In gathering the information for this Review to populate the comprehensive Table 1, we found many inconsistencies in the literature describing new mouse lines. It is crucial that descriptions are as complete as possible to define the specific pathology of a model, including reporting the absence of important features, such as MN degeneration, and other negative results. The use of Animal Research: Reporting of *In Vivo* Experiments (ARRIVE) guidelines (Kilkenny et al., 2014) will improve reporting of mouse model phenotypes. In addition, it is critical to make new models freely available via The European Mouse Mutant Archive (EMMA) or The Jackson Laboratory (JAX).

The complexities of ALS are clearly exemplified by the wide array of phenotypes arising in the plethora of mouse models available. If anything, the past decades of research into ALS have shown us that to improve our understanding of disease pathogenesis, the community must embrace its complexities and work with different models. In the near future, integrating data from multiple sources, mouse and human, *in vivo* and *in vitro*, should allow us to build a more complete picture of health and disease states, over a lifetime. However, ultimately, we must relate our findings back to humans, and cell, organoid and clinical models remain essential for cross-referencing and validating the findings from mouse studies.

Acknowledgements

We thank Dr Pietro Fratta and Dr Agnieszka Ule for critical reading of the manuscript.

Competing interests

The authors declare no competing or financial interests.

Funding

This work was supported by the Medical Research Council [MC_EX_MR/N501931/1 and MR/R005184/1 to E.M.C.F.], the Motor Neurone Disease Association [10/442 to E.M.C.F.], the Miguel Servet Programme of the Instituto de Salud Carlos III [CP15/00153 and PI17/00244 to A.A.-A.] and the Collaborative Center for X-Linked Dystonia Parkinsonism [to E.M.C.F. and C.M.].

References

- Acevedo-Aroza, A., Wells, S., Potter, P., Kelly, M., Cox, R. D. and Brown, S. D. M. (2008). ENU mutagenesis, a way forward to understand gene function. *Annu. Rev. Genomics Hum. Genet.* **9**, 49–69.
- Acevedo-Aroza, A., Kalmár, B., Essa, S., Ricketts, T., Joyce, P., Kent, R., Rowe, C., Parker, A., Gray, A., Hafezparast, M. et al. (2011). A comprehensive assessment of the *SOD1*G93A low-copy transgenic mouse, which models human amyotrophic lateral sclerosis. *Dis. Model. Mech.* **4**, 686–700.
- Achilli, F., Boyle, S., Kieran, D., Chia, R., Hafezparast, M., Martin, J. E., Schiavo, G., Greensmith, L., Bickmore, W. and Fisher, E. M. C. (2005). The *SOD1* transgene in the G93A mouse model of amyotrophic lateral sclerosis lies on distal mouse chromosome 12. *Amyotroph Lateral Scler.* **6**, 111–114.
- Alexander, G. M., Erwin, K. L., Byers, N., Deitch, J. S., Augelli, B. J., Blankenhorn, E. P. and Heiman-Patterson, T. D. (2004). Effect of transgene copy number on survival in the G93A *SOD1* transgenic mouse model of ALS. *Mol. Brain Res.* **130**, 7–15.
- Aliaga, L., Lai, C., Yu, J., Chub, N., Shim, H., Sun, L., Xie, C., Yang, W.-J., Lin, X., O'donovan, M. J. et al. (2013). Amyotrophic lateral sclerosis-related VAPB P56S mutation differentially affects the function and survival of corticospinal and spinal motor neurons. *Hum. Mol. Genet.* **22**, 4293–4305.
- Arnold, E. S., Ling, S.-C., Huelga, S. C., Lagier-Tourenne, C., Polymenidou, M., Ditsworth, D., Kordasiewicz, H. B., McAlonis-Downes, M., Platoshyn, O., Parone, P. A. et al. (2013). ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. *Proc. Natl Acad. Sci. USA* **110**, E736–E745.
- Badadani, M., Nalbandian, A., Watts, G. D., Vesa, J., Kitazawa, M., Su, H., Tanaja, J., Dec, E., Wallace, D. C., Mukherjee, J. et al. (2010). VCP associated inclusion body myopathy and paget disease of bone knock-in mouse model exhibits tissue pathology typical of human disease. *PLoS ONE* **5**, e13183.
- Balendra, R. and Isaacs, A. M. (2018). C9orf72-mediated ALS and FTD: multiple pathways to disease. *Nat. Rev. Neurol.* **14**, 544–558.
- Bannwarth, S., Ait-El-Mkadem, S., Chaussent, A., Genin, E. C., Lacas-Gervais, S., Fragaki, K., Berg-Alonso, L., Kageyama, Y., Serre, V., Moore,

- D. G. et al. (2014). A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. *Brain* **137**, 2329-2345.
- Beers, D. R., Henkel, J. S., Xiao, Q., Zhao, W., Wang, J., Yen, A. A., Siklos, L., Mckercher, S. R. and Appel, S. H. (2006). Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. *Proc. Natl Acad. Sci. USA* **103**, 16021-16026.
- Brenner, D., Yilmaz, R., Müller, K., Grehl, T., Petri, S., Meyer, T., Grosskreutz, J., Weydt, P., Ruf, W., Neuwirth, C. et al. (2018). Hot-spot KIF5A mutations cause familial ALS. *Brain* **141**, 688-697.
- Brown, R. H. and Al-Chalabi, A. (2017). Amyotrophic lateral sclerosis. *N. Engl. J. Med.* **377**, 162-172.
- Brujin, L. I., Becher, M. W., Lee, M. K., Anderson, K. L., Jenkins, N. A., Copeland, N. G., Sisodia, S. S., Rothstein, J. D., Borchelt, D. R., Price, D. L. et al. (1997). ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. *Neuron* **18**, 327-338.
- Brujin, L. I., Miller, T. M. and Cleveland, D. W. (2004). Unraveling the mechanisms involved in motor neuron degeneration in ALS. *Annu. Rev. Neurosci.* **27**, 723-749.
- Bunton-Stasyshyn, R. K. A., Saccon, R. A., Fratta, P. and Fisher, E. M. C. (2015). SOD1 function and its implications for amyotrophic lateral sclerosis pathology. *Neuroscientist* **21**, 519-529.
- Cannon, A., Yang, B., Knight, J., Farnham, I. M., Zhang, Y., Wuertz, C. A., D'Alton, S., Lin, W., Castaneda-Casey, M., Rousseau, L. et al. (2012). Neuronal sensitivity to TDP-43 overexpression is dependent on timing of induction. *Acta Neuropathol.* **123**, 807-823.
- Chang-Hong, R., Wada, M., Koyama, S., Kimura, H., Arawaka, S., Kawanami, T., Kurita, K., Kadota, Y., Aoki, M., Itoyama, Y. et al. (2005). Neuroprotective effect of oxidized galectin-1 in a transgenic mouse model of amyotrophic lateral sclerosis. *Exp. Neurol.* **194**, 203-211.
- Charcot, J. M. and Joffroy, A. (1869). Deux cas d'atrophie musculaire progressive avec lésions de la substance grise et des faisceaux antero-latéraux de la moelle épinière. *Arch. Physiol. Neurol. Pathol.* **2**, 744-754.
- Chen, Y.-Z., Bennett, C. L., Huynh, H. M., Blair, I. P., Puls, I., Irobi, J., Dierick, I., Abel, A., Kennerson, M. L., Rabin, B. A. et al. (2004). DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). *Am. J. Hum. Genet.* **74**, 1128-1135.
- Chou, C.-C., Zhang, Y., Umoh, M. E., Vaughan, S. W., Lorenzini, I., Liu, F., Sayegh, M., Donlin-Asp, P. G., Chen, Y. H., Duong, D. M. et al. (2018). TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. *Nat. Neurosci.* **21**, 228-239.
- Cirulli, E. T., Lasseigne, B. N., Petrovski, S., Sapp, P. C., Dion, P. A., Leblond, C. S., Couthouis, J., Lu, Y.-F., Wang, Q., Krueger, B. J. et al. (2015). Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. *Science* **347**, 1436-1441.
- Costa, J. and De Carvalho, M. (2016). Emerging molecular biomarker targets for amyotrophic lateral sclerosis. *Clin. Chim. Acta* **455**, 7-14.
- Custer, S. K., Neumann, M., Lu, H., Wright, A. C. and Taylor, J. P. (2010). Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone. *Hum. Mol. Genet.* **19**, 1741-1755.
- Dejesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. C. A., Flynn, H., Adamson, J. et al. (2011). Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-Linked FTD and ALS. *Neuron* **72**, 245-256.
- Deng, H.-X., Shi, Y., Furukawa, Y., Zhai, H., Fu, R., Liu, E., Gorrie, G. H., Khan, M. S., Hung, W.-Y., Bigio, E. H. et al. (2006). Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria. *Proc. Natl Acad. Sci. USA* **103**, 7142-7147.
- Deng, H.-X., Chen, W., Hong, S.-T., Boycott, K. M., Gorrie, G. H., Siddique, N., Yang, Y., Fecto, F., Shi, Y., Zhai, H. et al. (2011). Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. *Nature* **477**, 211-215.
- Devoy, A., Kalmár, B., Stewart, M., Park, H., Burke, B., Noy, S. J., Redhead, Y., Humphrey, J., Lo, K., Jaeger, J. et al. (2017). Humanized mutant FUS drives progressive motor neuron degeneration without aggregation in 'FUSDelta14' knockin mice. *Brain* **140**, 2797-2805.
- Fecto, F. (2011). SQSTM1 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis. *Arch. Neurol.* **68**, 1440.
- Filali, M., Lalonde, R. and Rivest, S. (2011). Sensorimotor and cognitive functions in a SOD1G37R transgenic mouse model of amyotrophic lateral sclerosis. *Behav. Brain Res.* **225**, 215-221.
- Fischer, L. R., Igoudjil, A., Magrané, J., Li, Y., Hansen, J. M., Manfredi, G. and Glass, J. D. (2011). SOD1 targeted to the mitochondrial intermembrane space prevents motor neuropathy in the Sod1 knockout mouse. *Brain* **134**, 196-209.
- Fratta, P., Sivakumar, P., Humphrey, J., Lo, K., Ricketts, T., Oliveira, H., Brito-Armas, J. M., Kalmár, B., Ule, A., Yu, Y. et al. (2018). Mice with endogenous TDP-43 mutations exhibit gain of splicing function and characteristics of amyotrophic lateral sclerosis. *EMBO J.* **37**, e98684.
- Freischmidt, A., Wieland, T., Richter, B., Ruf, W., Schaeffer, V., Müller, K., Marroquin, N., Nordin, F., Hübers, A., Weydt, P. et al. (2015). Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. *Nat. Neurosci.* **18**, 631-636.
- Goldstein, O., Gana-Weisz, M., Nefussy, B., Vainer, B., Nayshool, O., Bar-Shira, A., Traynor, B. J., Drory, V. E. and Orr-Urtreger, A. (2018). High frequency of C9orf72 hexanucleotide repeat expansion in amyotrophic lateral sclerosis patients from two founder populations sharing the same risk haplotype. *Neurobiol. Aging* **64**, 160.e1-160.e7.
- Goodwin, L. O., Splinter, E., Davis, T. L., Urban, R., He, H., Braun, R. E., Chesler, E. J., Kumar, V., Van Min, M., Ndukum, J. et al. (2017). Large-scale discovery of mouse transgenic integration sites reveals frequent structural variation and insertional mutagenesis. *bioRxiv*, 1-27.
- Gordon, D., Dafinca, R., Scaber, J., Alegre-Abarategui, J., Farrimond, L., Scott, C., Biggs, D., Kent, L., Oliver, P. L., Davies, B. et al. (2019). Single-copy expression of an amyotrophic lateral sclerosis-linked TDP-43 mutation (M337V) in BAC transgenic mice leads to altered stress granule dynamics and progressive motor dysfunction. *Neurobiol. Dis.* **121**, 148-162.
- Gorrie, G. H., Fecto, F., Radzicki, D., Weiss, C., Shi, Y., Dong, H., Zhai, H., Fu, R., Liu, E., Li, S. et al. (2014). Dendritic spinopathy in transgenic mice expressing ALS/dementia-linked mutant UBQLN2. *Proc. Natl Acad. Sci. USA* **111**, 14524-14529.
- Graffmo, K. S., Forsberg, K., Bergh, J., Birve, A., Zetterstrom, P., Andersen, P. M., Marklund, S. L. and Brannstrom, T. (2013). Expression of wild-type human superoxide dismutase-1 in mice causes amyotrophic lateral sclerosis. *Hum. Mol. Genet.* **22**, 51-60.
- Guerrero, E. N., Wang, H., Mitra, J., Hegde, P. M., Stowell, S. E., Liachko, N. F., Kraemer, B. C., Garruto, R. M., Rao, K. S. and Hegde, M. L. (2016). TDP-43/FUS in motor neuron disease: complexity and challenges. *Prog. Neurobiol.* **145-146**, 78-97.
- Gurney, M., Pu, H., Chiu, A., Dal Canto, M., Polchow, C., Alexander, D., Caliendo, J., Hentati, A., Kwon, Y., Deng, H. et al. (1994). Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. *Science* **264**, 1772-1775.
- Han-Xiang, D., Hujun, J., Ronggen, F., Hong, Z., Yong, S., Erdong, L., Makito, H., Mauro, C. D. C. and Teepu, S. (2008). Molecular dissection of ALS-associated toxicity of SOD1 in transgenic mice using an exon-fusion approach. *Hum. Mol. Genet.* **17**, 2310-2319.
- Hatzipetros, T., Bogdanik, L. P., Tassinari, V. R., Kidd, J. D., Moreno, A. J., Davis, C., Osborne, M., Austin, A., Vieira, F. G., Lutz, C. et al. (2014). C57BL/6J congenic Prp-TDP43A315T mice develop progressive neurodegeneration in the myenteric plexus of the colon without exhibiting key features of ALS. *Brain Res.* **1584**, 59-72.
- Heiman-Patterson, T. D., Sher, R. B., Blankenhorn, E. A., Alexander, G., Deitch, J. S., Kunst, C. B., Maragakis, N. and Cox, G. (2011). Effect of genetic background on phenotype variability in transgenic mouse models of amyotrophic lateral sclerosis: a window of opportunity in the search for genetic modifiers. *Amyotroph Lateral Scler.* **12**, 79-86.
- Hjerpe, R., Bett, J. S., Keuss, M. J., Solovyova, A., McWilliams, T. G., Johnson, C., Sahu, I., Varghese, J., Wood, N., Wightman, M. et al. (2016). UBQLN2 mediates autophagy-independent protein aggregate clearance by the proteasome. *Cell* **166**, 935-949.
- Huynh, W., Simon, N. G., Grosskreutz, J., Turner, M. R., Vucic, S. and Kiernan, M. C. (2016). Assessment of the upper motor neuron in amyotrophic lateral sclerosis. *Clin. Neurophysiol.* **127**, 2643-2660.
- Igaz, L. M., Kwong, L. K., Lee, E. B., Chen-Plotkin, A., Swanson, E., Unger, T., Malunda, J., Xu, Y., Winton, M. J., Trojanowski, J. Q. et al. (2011). Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. *J. Clin. Invest.* **121**, 726-738.
- Ingre, C., Roos, P. M., Piehl, F., Kamel, F. and Fang, F. (2015). Risk factors for amyotrophic lateral sclerosis. *Clin. Epidemiol.* **7**, 181-193.
- Jaarsma, D., Haasdijk, E. D., Grashorn, J. A. C., Hawkins, R., Van Duijn, W., Verspaget, H. W., London, J. and Holstege, J. C. (2000). Human Cu/Zn Superoxide Dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates motoneuron disease in mice expressing a familial amyotrophic lateral sclerosis mutant SOD1. *Neurobiol. Dis.* **7**, 623-643.
- Jaarsma, D., Teuling, E., Haasdijk, E. D., De Zeeuw, C. I. and Hoogenraad, C. C. (2008). Neuron-specific expression of mutant superoxide dismutase is sufficient to induce amyotrophic lateral sclerosis in transgenic mice. *J. Neurosci.* **28**, 2075-2088.
- Janssens, J., Wils, H., Kleinberger, G., Joris, G., Cuijt, I., Ceuterick-De Groote, C., Van Broeckhoven, C. and Kumar-Singh, S. (2013). Overexpression of ALS-associated p.M337V human TDP-43 in mice worsens disease features compared to wild-type human TDP-43 mice. *Mol. Neurobiol.* **48**, 22-35.
- Johnson, J. O., Mandrioli, J., Benatar, M., Abramson, Y., Van Deerlin, V. M., Trojanowski, J. Q., Gibbs, J. R., Brunetti, M., Gronka, S., Wu, J. et al. (2010). Exome sequencing reveals VCP mutations as a cause of familial ALS. *Neuron* **68**, 857-864.

- Johnson, J. O., Pioro, E. P., Boehringer, A., Chia, R., Feit, H., Renton, A. E., Pliner, H. A., Abramzon, Y., Marangi, G., Winborn, B. J. et al. (2014). Mutations in the *Matrin 3* gene cause familial amyotrophic lateral sclerosis. *Nat. Neurosci.* **17**, 664-666.
- Jonsson, P. A., Ernhill, K., Andersen, P. M., Bergemalm, D., Brännström, T., Gredal, O., Nilsson, P. and Marklund, S. L. (2004). Minute quantities of misfolded mutant superoxide dismutase-1 cause amyotrophic lateral sclerosis. *Brain* **127**, 73-88.
- Jonsson, P. A., Graffmo, K. S., Andersen, P. M., Brännström, T., Lindberg, M., Oliveberg, M. and Marklund, S. L. (2006). Disulphide-reduced superoxide dismutase-1 in CNS of transgenic amyotrophic lateral sclerosis models. *Brain* **129**, 451-464.
- Joyce, P. I., Mcgoldrick, P., Saccon, R. A., Weber, W., Fratta, P., West, S. J., Zhu, N., Carter, S., Phatak, V., Stewart, M. et al. (2015). A novel SOD1-ALS mutation separates central and peripheral effects of mutant SOD1 toxicity. *Hum. Mol. Genet.* **24**, 1883-1897.
- Kalliokoski, O., Teilmann, A. C., Jacobsen, K. R., Abelson, K. S. P. and Hau, J. (2014). The lonely mouse – single housing affects serotonergic signaling integrity measured by 8-OH-DPAT-induced hypothermia in male mice. *PLoS ONE* **9**, e111065.
- Karch, C. M. and Borchelt, D. R. (2010). Aggregation modulating elements in mutant human superoxide dismutase 1. *Arch. Biochem. Biophys.* **503**, 175-182.
- Kaur, S. J., Mckeown, S. R. and Rashid, S. (2016). Mutant SOD1 mediated pathogenesis of Amyotrophic Lateral Sclerosis. *Gene* **577**, 109-118.
- Keays, D. A., Clark, T. G., Campbell, T. G., Broxholme, J. and Valdar, W. (2007). Estimating the number of coding mutations in genotypic and phenotypic driven N-ethyl-N-nitrosourea (ENU) screens: revisited. *Mamm. Genome* **18**, 123-124.
- Kilkenny, C., Browne, W., Cuthill, I., Emerson, M. and Altman, D. (2014). Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. *Animals* **4**, 35-44.
- Kramer, B. C., Schuck, T., Wheeler, J. M., Robinson, L. C., Trojanowski, J. Q., Lee, V. M. Y. and Schellenberg, G. D. (2010). Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. *Acta Neuropathol.* **119**, 409-419.
- Larroquette, F., Seto, L., Gaub, P. L., Kamal, B., Wallis, D., Larivière, R., Vallée, J., Robitaille, R. and Tsuda, H. (2015). Vapb /Amyotrophic lateral sclerosis 8 knock-in mice display slowly progressive motor behavior defects accompanying ER stress and autophagic response. *Hum. Mol. Genet.* **24**, 6515-6529.
- Le, N. T. T., Chang, L., Kovlyagina, I., Georgiou, P., Safren, N., Braunstein, K. E., Kvara, M. D., Van Dyke, A. M., Legates, T. A., Phillips, T. et al. (2016). Motor neuron disease, TDP-43 pathology, and memory deficits in mice expressing ALS-FTD-linked UBQLN2 mutations. *Proc. Natl Acad. Sci. USA* **113**, E7580-E7589.
- Li, H.-F. and Wu, Z.-Y. (2016). Genotype-phenotype correlations of amyotrophic lateral sclerosis. *Translational Neurodegeneration* **5**, 3.
- Lino, M. M., Schneider, C. and Caroni, P. (2002). Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. *J. Neurosci.* **22**, 4825-4832.
- Liu, E. Y., Cali, C. P. and Lee, E. B. (2017). RNA metabolism in neurodegenerative disease. *Dis. Model. Mech.* **10**, 509-518.
- López-Erauskin, J., Tadokoro, T., Baughn, M. W., Myers, B., McAlonis-Downes, M., Chillón-Marinas, C., Asiaban, J. N., Artates, J., Bui, A. T., Vetto, A. P. et al. (2018). ALS/FTD-linked mutation in FUS suppresses intra-axonal protein synthesis and drives disease without nuclear loss-of-function of FUS. *Neuron* **100**, 816-830.e7.
- Mancuso, R., Oliván, S., Mancera, P., Pastén-Zamorano, A., Manzano, R., Casas, C., Osta, R. and Navarro, X. (2012). Effect of genetic background on onset and disease progression in the SOD1-G93A model of amyotrophic lateral sclerosis. *Amyotroph Lateral Scler.* **13**, 302-310.
- Marin, B., Logroschino, G., Boumédiène, F., Labrunie, A., Couratier, P., Babron, M.-C., Leutenegger, A. L., Preux, P. M. and Beghi, E. (2016). Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin. *Eur. J. Epidemiol.* **31**, 229-245.
- Maruyama, H., Morino, H., Ito, H., Izumi, Y., Kato, H., Watanabe, Y., Kinoshita, Y., Kamada, M., Nodera, H., Suzuki, H. et al. (2010). Mutations of optineurin in amyotrophic lateral sclerosis. *Nature* **465**, 223-226.
- Mitchell, J. C., Mcgoldrick, P., Vance, C., Hortobagyi, T., Sreedharan, J., Rogelj, B., Tudor, E. L., Smith, B. N., Klasen, C., Miller, C. C. J. et al. (2013). Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion. *Acta Neuropathol.* **125**, 273-288.
- Mitchell, J. C., Constable, R., So, E., Vance, C., Scotter, E., Glover, L., Hortobagyi, T., Arnold, E. S., Ling, S.-C., McAlonis, M. et al. (2015). Wild type human TDP-43 potentiates ALS-linked mutant TDP-43 driven progressive motor and cortical neuron degeneration with pathological features of ALS. *Acta Neuropathol. Commun.* **3**, 36.
- Muñoz-Fuentes, V., Cacheiro, P., Meehan, T. F., Aguilar-Pimentel, J. A., Brown, S. D. M., Flenniken, A. M., Flicek, P., Galli, A., Mashhadi, H. H., Hrabě de Angelis, M. et al. (2018). The International Mouse Phenotyping Consortium (IMPC): a functional catalogue of the mammalian genome that informs conservation. *Conserv. Genet.* **19**, 995-1005.
- Nalbandian, A., Llewellyn, K. J., Kitazawa, M., Yin, H. Z., Badadani, M., Khanlou, N., Edwards, R., Nguyen, C., Mukherjee, J., Mozaffar, T. et al. (2012). The homozygote VCP155H/R155H mouse model exhibits accelerated human VCP-associated disease pathology. *PLoS ONE* **7**, e46308.
- Nalbandian, A., Llewellyn, K. J., Badadani, M., Yin, H. Z., Nguyen, C., Katheria, V., Watts, G., Mukherjee, J., Vesa, J., Caiozzo, V. et al. (2013). A progressive translational mouse model of human valosin-containing protein disease: the VCP R155H/+ mouse. *Muscle Nerve* **47**, 260-270.
- Nardo, G., Iennaco, R., Fusi, N., Heath, P. R., Marino, M., Trolese, M. C., Ferraiuolo, L., Lawrence, N., Shaw, P. J. and Bendotti, C. (2013). Transcriptomic indices of fast and slow disease progression in two mouse models of amyotrophic lateral sclerosis. *Brain* **136**, 3305-3332.
- Nishimura, A. L., Mitne-Neto, M., Silva, H. C. A., Richieri-Costa, A., Middleton, S., Cascio, D., Kok, F., Oliveira, J. R. M., Gillingwater, T., Webb, J. et al. (2004). A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. *Am. J. Hum. Genet.* **75**, 822-831.
- Potter, P. K., Bowl, M. R., Jeyarajan, P., Wisby, L., Blease, A., Goldsworthy, M. E., Simon, M. M., Greenaway, S., Michel, V., Barnard, A. et al. (2016). Novel gene function revealed by mouse mutagenesis screens for models of age-related disease. *Nat. Commun.* **7**, 12444.
- Pramatarova, A., Laganière, J., Roussel, J., Brisebois, K. and Rouleau, G. A. (2001). Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. *J. Neurosci.* **21**, 3369-3374.
- Prudencio, M., Durazo, A., Whitelegue, J. P. and Borchelt, D. R. (2009). Modulation of mutant superoxide dismutase 1 aggregation by co-expression of wild-type enzyme. *J. Neurochem.* **108**, 1009-1018.
- Qiu, H., Lee, S., Shang, Y., Wang, W.-Y., Au, K. F., Kamiya, S., Barmada, S. J., Finkbeiner, S., Lui, H., Carlton, C. E. et al. (2014). ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects. *J. Clin. Investig.* **124**, 981-999.
- Quarta, E., Bravi, R., Scambi, I., Mariotti, R. and Minciaccchi, D. (2015). Increased anxiety-like behavior and selective learning impairments are concomitant to loss of hippocampal interneurons in the presymptomatic SOD1(G93A) ALS mouse model. *J. Comp. Neurol.* **523**, 1622-1638.
- Renton, A. E., Majounie, E., Waite, A., Simón-Sánchez, J., Rollinson, S., Gibbs, J. R., Schymick, J. C., Laaksovirta, H., van Swieten, J. C., Myllykangas, L. et al. (2011). A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-Linked ALS-FTD. *Neuron* **72**, 257-268.
- Riboldi, G., Nizzardo, M., Simone, C., Falcone, M., Bresolin, N., Comi, G. P. and Corti, S. (2011). ALS genetic modifiers that increase survival of SOD1 mice and are suitable for therapeutic development. *Prog. Neurobiol.* **95**, 133-148.
- Ricketts, T., Mcgoldrick, P., Fratta, P., De Oliveira, H. M., Kent, R., Phatak, V., Brandner, S., Blanco, G., Greensmith, L., Acevedo-Arozena, A. et al. (2014). A nonsense mutation in mouse Tardp affects TDP43 alternative splicing activity and causes limb-clasping and body tone defects. *PLoS ONE* **9**, e85962.
- Ripps, M. E., Huntley, G. W., Hof, P. R., Morrison, J. H. and Gordon, J. W. (1995). Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. *Proc. Natl Acad. Sci. USA* **92**, 689-693.
- Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X. et al. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. *Nature* **362**, 59-62.
- Saccon, R. A., Bunton-Stasyshyn, R. K. A., Fisher, E. M. C. and Fratta, P. (2013). Is SOD1 loss of function involved in amyotrophic lateral sclerosis? *Brain* **136**, 2342-2358.
- Scckic-Zahirovic, J., Sendscheid, O., El Oussini, H., Jambeau, M., Sun, Y., Mersmann, S., Wagner, M., Dieterlé, S., Sinniger, J., Dirrig-Grosch, S. et al. (2016). Toxic gain of function from mutant FUS protein is crucial to trigger cell autonomous motor neuron loss. *EMBO J.* **35**, 1077-1097.
- Scckic-Zahirovic, J., Oussini, H. E., Mersmann, S., Drenner, K., Wagner, M., Sun, Y., Allmeroth, K., Dieterlé, S., Sinniger, J., Dirrig-Grosch, S. et al. (2017). Motor neuron intrinsic and extrinsic mechanisms contribute to the pathogenesis of FUS-associated amyotrophic lateral sclerosis. *Acta Neuropathol.* **133**, 887-906.
- Seetharaman, S. V., Taylor, A. B., Holloway, S. and Hart, P. J. (2010). Structures of mouse SOD1 and human/mouse SOD1 chimeras. *Arch. Biochem. Biophys.* **503**, 183-190.
- Septon, C. F., Tang, A. A., Kulkarni, A., West, J., Brooks, M., Stubblefield, J. J., Liu, Y., Zhang, M. Q., Green, C. B., Huber, K. M. et al. (2014). Activity-dependent FUS dysregulation disrupts synaptic homeostasis. *Proc. Natl Acad. Sci. USA* **111**, E4769-E4778.
- Shan, X., Chiang, P.-M., Price, D. L. and Wong, P. C. (2010). Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. *Proc. Natl Acad. Sci. USA* **107**, 16325-16330.
- Sharma, A., Lyashchenko, A. K., Lu, L., Nasrabad, S. E., Elmaleh, M., Mendelsohn, M., Nemes, A., Tapia, J. C., Mentis, G. Z. and Schneider, N. A. (2016). ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function. *Nat. Commun.* **7**, 10465.

- Shibata, N. (2001). Transgenic mouse model for familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation. *Neuropathology* **21**, 82-92.
- Shiihashi, G., Ito, D., Yagi, T., Nihei, Y., Ebine, T. and Suzuki, N. (2016). Mislocated FUS is sufficient for gain-of-toxic-function amyotrophic lateral sclerosis phenotypes in mice. *Brain* **139**, 2380-2394.
- Sorrells, A. D., Corcoran-Gomez, K., Eckert, K. A., Fahey, A. G., Hoots, B. L., Charleston, L. B., Charleston, J. S., Roberts, C. R. and Markowitz, H. (2009). Effects of environmental enrichment on the amyotrophic lateral sclerosis mouse model. *Lab. Anim.* **43**, 182-190.
- Spiller, K. J., Restrepo, C. R., Khan, T., Dominique, M. A., Fang, T. C., Canter, R. G., Roberts, C. J., Miller, K. R., Ransohoff, R. M., Trojanowski, J. Q. et al. (2018). Microglia-mediated recovery from ALS-relevant motor neuron degeneration in a mouse model of TDP-43 proteinopathy. *Nat. Neurosci.* **21**, 329-340.
- Srivastava, A., Philip, V. M., Greenstein, I., Rowe, L. B., Barter, M., Lutz, C. and Reinholdt, L. G. (2014). Discovery of transgene insertion sites by high throughput sequencing of mate pair libraries. *BMC Genomics* **15**, 367.
- St-Amour, I., Turgeon, A., Goupil, C., Planel, E. and Hébert, S. S. (2018). Co-occurrence of mixed proteinopathies in late-stage Huntington's disease. *Acta Neuropathol.* **135**, 249-265.
- Stallings, N. R., Puttaparthi, K., Luther, C. M., Burns, D. K. and Elliott, J. L. (2010). Progressive motor weakness in transgenic mice expressing human TDP-43. *Neurobiol. Dis.* **40**, 404-414.
- Stottmann, R. and Beier, D. (2014). ENU mutagenesis in the mouse. *Curr. Protoc. Hum. Genet.* **94**, 15.4.1-15.4.10.
- Stribl, C., Samara, A., Trümbach, D., Peis, R., Neumann, M., Fuchs, H., Gailus-Durner, V., Hrabě de Angelis, M., Rathkolb, B., Wolf, E. et al. (2014). Mitochondrial dysfunction and decrease in body weight of a transgenic knock-in mouse model for TDP-43. *J. Biol. Chem.* **289**, 10769-10784.
- Sundberg, J. P. and Schofield, P. N. (2018). Living inside the box: environmental effects on mouse models of human disease. *Dis. Model. Mech.* **11**, dmm035360.
- Swarup, V., Phaneuf, D., Bareil, C., Robertson, J., Rouleau, G. A., Kriz, J. and Julien, J.-P. (2011). Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. *Brain* **134**, 2610-2626.
- Tarlarini, C., Lunetta, C., Mosca, L., Avemaria, F., Riva, N., Mantero, V., Maestri, E., Quattrini, A., Corbo, M., Melazzini, M. G. et al. (2015). Novel FUS mutations identified through molecular screening in a large cohort of familial and sporadic amyotrophic lateral sclerosis. *Eur. J. Neurol.* **22**, 1474-1481.
- Tibshirani, M., Tradewell, M. L., Mattina, K. R., Minotti, S., Yang, W., Zhou, H., Strong, M. J., Hayward, L. J. and Durham, H. D. (2015). Cytoplasmic sequestration of FUS/TLS associated with ALS alters histone marks through loss of nuclear protein arginine methyltransferase 1. *Hum. Mol. Genet.* **24**, 773-786.
- Tobisawa, S., Hozumi, Y., Arawaka, S., Koyama, S., Wada, M., Nagai, M., Aoki, M., Itoyama, Y., Goto, K. and Kato, T. (2003). Mutant SOD1 linked to familial amyotrophic lateral sclerosis, but not wild-type SOD1, induces ER stress in COS7 cells and transgenic mice. *Biochem. Biophys. Res. Commun.* **303**, 496-503.
- Tosh, J. L., Rickman, M., Rhymes, E., Norona, F. E., Clayton, E., Mucke, L., Isaacs, A. M., Fisher, E. M. C. and Wiseman, F. K. (2017). The integration site of the APP transgene in the J20 mouse model of Alzheimer's disease. *Wellcome Open Res.* **2**, 84.
- Tsai, K.-J., Yang, C.-H., Fang, Y.-H., Cho, K.-H., Chien, W.-L., Wang, W.-T., Wu, T.-W., Lin, C.-P., Fu, W.-M. and Shen, C.-K. J. (2010). Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLN-U. *J. Exp. Med.* **207**, 1661-1673.
- Turner, B. and Talbot, K. (2008). Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. *Prog. Neurobiol.* **85**, 94-134.
- Urushitani, M., Ezzi, S. A. and Julien, J.-P. (2007). Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. *Proc. Natl Acad. Sci. USA* **104**, 2495-2500.
- Vallarola, A., Sironi, F., Tortarolo, M., Gatto, N., De Gioia, R., Pasetto, L., De Paola, M., Mariani, A., Ghosh, S., Watson, R. et al. (2018). RNS60 exerts therapeutic effects in the SOD1 ALS mouse model through protective glia and peripheral nerve rescue. *J. Neuroinflammation* **15**, 65.
- Van Damme, P., Robberecht, W. and Van Den Bosch, L. (2017). Modelling amyotrophic lateral sclerosis: progress and possibilities. *Dis. Model. Mech.* **10**, 537-549.
- Walker, A. K., Spiller, K. J., Ge, G., Zheng, A., Xu, Y., Zhou, M., Tripathy, K., Kwong, L. K., Trojanowski, J. Q. and Lee, V. M.-Y. (2015). Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43. *Acta Neuropathol.* **130**, 643-660.
- Wang, J., Xu, G., Gonzales, V., Coonfield, M., Fromholt, D., Copeland, N. G., Jenkins, N. A. and Borchelt, D. R. (2002). Fibrillar inclusions and motor neuron degeneration in transgenic mice expressing superoxide dismutase 1 with a disrupted copper-binding site. *Neurobiol. Dis.* **10**, 128-138.
- Wang, J., Slunt, H., Gonzales, V., Fromholt, D., Coonfield, M., Copeland, N. G., Jenkins, N. A. and Borchelt, D. R. (2003). Copper-binding-site-null SOD1 causes ALS in transgenic mice: aggregates of non-native SOD1 delineate a common feature. *Hum. Mol. Genet.* **12**, 2753-2764.
- Wang, J., Xu, G., Li, H., Gonzales, V., Fromholt, D., Karch, C., Copeland, N. G., Jenkins, N. A. and Borchelt, D. R. (2005). Somatodendritic accumulation of misfolded SOD1-L126Z in motor neurons mediates degeneration: α B-crystallin modulates aggregation. *Hum. Mol. Genet.* **14**, 2335-2347.
- Wang, L., Deng, H.-X., Grisotti, G., Zhai, H., Siddique, T. and Roos, R. P. (2009). Wild-type SOD1 overexpression accelerates disease onset of a G85R SOD1 mouse. *Hum. Mol. Genet.* **18**, 1642-1651.
- Watanabe, Y., Yasui, K., Nakano, T., Doi, K., Fukada, Y., Kitayama, M., Ishimoto, M., Kurihara, S., Kawashima, M., Fukuda, H. et al. (2005). Mouse motor neuron disease caused by truncated SOD1 with or without C-terminal modification. *Mol. Brain Res.* **135**, 12-20.
- Wegorzewska, I., Bell, S., Cairns, N. J., Miller, T. M. and Baloh, R. H. (2009). TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. *Proc. Natl. Acad. Sci. USA* **106**, 18809-18814.
- Weihl, C. C., Miller, S. E., Hanson, P. I. and Pestronk, A. (2007). Transgenic expression of inclusion body myopathy associated mutant p97/VCP causes weakness and ubiquitinated protein inclusions in mice. *Hum. Mol. Genet.* **16**, 919-928.
- White, M. A., Kim, E., Duffy, A., Adalbert, R., Phillips, B. U., Peters, O. M., Stephenson, J., Yang, S., Massenzio, F., Lin, Z. et al. (2018). TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. *Nat. Neurosci.* **21**, 552-563.
- Wils, H., Kleinberger, G., Janssens, J., Pereson, S., Joris, G., Cuijt, I., Smits, V., Ceuterick-De Groote, C., Van Broeckhoven, C. and Kumar-Singh, S. (2010). TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. *Proc. Natl Acad. Sci. USA* **107**, 3858-3863.
- Wong, P. C., Pardo, C. A., Borchelt, D. R., Lee, M. K., Copeland, N. G., Jenkins, N. A., Sisodia, S. S., Cleveland, D. W. and Price, D. L. (1995). An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. *Neuron* **14**, 1105-1116.
- Wu, D.-C., Re, D. B., Nagai, M., Ischiropoulos, H. and Przedborski, S. (2006). The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice. *Proc. Natl Acad. Sci. USA* **103**, 12132-12137.
- Wu, C.-H., Fallini, C., Ticozzi, N., Keagle, P. J., Sapp, P. C., Piotrowska, K., Lowe, P., Koppers, M., McKenna-Yasek, D., Baron, D. M. et al. (2012). Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. *Nature* **488**, 499-503.
- Xu, Y.-F., Gendron, T. F., Zhang, Y.-J., Lin, W.-L., D'Alton, S., Sheng, H., Casey, M. C., Tong, J., Knight, J., Yu, X. et al. (2010). Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. *J. Neurosci.* **30**, 10851-10859.
- Xu, Y.-F., Zhang, Y.-J., Lin, W.-L., Cao, X., Stetler, C., Dickson, D. W., Lewis, J. and Petrucelli, L. (2011). Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice. *Mol. Neurodegener.* **6**, 73.
- Yin, H. Z., Nalbandian, A., Hsu, C.-I., Li, S., Llewellyn, K. J., Mozaffar, T., Kimonis, V. E. and Weiss, J. H. (2012). Slow development of ALS-like spinal cord pathology in mutant valosin-containing protein gene knock-in mice. *Cell Death Dis.* **3**, e374-e374.
- Zhang, X.-H., Tee, L. Y., Wang, X.-G., Huang, Q.-S. and Yang, S.-H. (2015). Off-target effects in CRISPR/Cas9-mediated genome engineering. *Mol. Ther. Nucleic Acids* **4**, e264.